TTR-FAP have been described more than 60 years ago by Corino Andrade in Porto (Brain, 1952) . This peculiar disease affected many families with an autosomal dominant transmission, in the third decade of life, characterized by a progressive peripheral neuropathy starting in the lower extremities with initial impairment of thermal and pain sensibilities associated with gastrointestinal disorders and loss of weight. Natural history has been reported by Paula Coutinho (1980) with progression in 3 stages of the disease : stage 1, a disease limited to the lower limbs and a patient is still walking without any help (5.6 years), stage II progressive motor loss in the lower limbs with steppage needing help for walking (4.8 years), and a stage III in which the patient is bedridden or confined to a wheelchair (2.3 years) . Death comes within an average time of 10.8 years. Late onset (LO>50 years) cases of V30M were reported in the 2000's, with a different phenotype marked by all sensory modalities involvement, relatively mild autonomic symptoms, predominantly in male patients and sporadic cases (50%). Three new phenotypes have been described in late onset cases more recently: upper limb onset neuropathy, ataxic neuropathy and motor neuropathy. In LO V30M, there is an earliest and rapid impact on locomotion, need for aid for walking within 3 years from onset, and a shorter survival 7.3 years (Koike et al, JNNP 2012) . There is genotype impact on severity and progression of the neuropathy and a correlation of Neuropathy Impairment Scores (NIS) and locomotion score PND (Adams et al, Neurology 2015 ; Mariani et al, in press ). The phenotype variety, frequent absence of family history and autonomic dysfunction in late onset cases contribute to delay diagnosis. The early and increase uptake of TTR gene testing should allow to increase the identification of TTR-FAP.
Potential treatment options to disrupt amyloid fibrils are lacking and cardiac manifestation is associated with poor prognosis. Thus, early identification of patients at risk for development of systemic ATTR amyloidosis is crucial to avoid deterioration of organ function and maintain quality of life. Predictive moleculargenetic testing of family members is the initial step to identify a patient at risk for hereditary ATTR amyloidosis. However, incomplete penetrance and high variability of age of onset of disease complicates the diagnostic strategy. Thus, regular screening is required for early identification of the disease. However, the question arises what diagnostic tools should be used for assessment of asymptomatic carriers of a TTR gene variant. Although endomyocardial biopsy has the highest sensitivity and specificity for detection of cardiac amyloidosis it is not capable for longitudinal evaluation in asymptomatic carriers. Non-invasive strategies are required to allow frequent testings with time intervals ranging between 6 and 24 months. ECG, echocardiography, cardiac magnetic resonance imaging, skeletal scintigraphy, and cardiac biomarkers are potential tools for assessment. In general, routine assessment should be based on ECG and echocardiography. Precise screening of ECG for any abnormalities including conduction disturbances, QRS or T-wave abnormalities is mandatory as abnormal findings are present in almost all patients with cardiac ATTR amyloidosis. Echocardiography assessment should include evaluation of diastolic function, longitudinal impairment, as well as speckle tracking. Cardiac MRI has become the gold standard for evaluation of cardiac morphology and function. Moreover, application of gadolinium allows characterization of the myocardium by a characteristic pattern of late gadolinium enhancement in cardiac amyloidosis. Despite high resolution images and excellent reproducibility, this technique is time consuming, cost intensive, and ultimately ira availability is limited to large centers. Recently, native cardiac T1 mapping has been reported to abnormal early during the clinical course. Cardiac retention of bone tracers has been reported to be specific for detection of ATTR amyloid. However, the clinical use for early identification remains debatable. Finally, longitudinal assessment is limited due to radioactivity. Cardiac biomarkers, including brain-natriuretic peptides and troponin T are sensitive indicators of myocardial stress and injury and appear to be an easy and useful tools for work-up of carriers. Due to lack of potential treatment options to disrupt amyloid fibrils the main goal in carriers of transthyretin variants is to dectect manifest amyloid disease as early as possible. From the cardiological point of view carriers of TTR variants should routinely be assessed by ECG, echocardiography with speckle tracking, and cardiac biomarkers. If available cardiac MRI with mapping techniques appears to be of additional benefit.
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When to decide to enroll a TTR-FAP patient in a Clinical Trial? Juan Buades Hospital Clínico San Carlos, Madrid, Spain Orphanet Journal of Rare Diseases 2015, 10(Suppl 1):I4 Background: The Transthyretin-Familial Amyloid Polyneuropathy (TTR-FAP) is a disease caused by deposition of mutant transthyretin (TTR), produced approximately 95% in the liver and the rest in the plexus choroideus and retina. In 1990 the first TTR-FAP patient liver transplant was performed. The liver transplant, which suppresses TTR synthesis, was the only treatment available to modify this disease until 2011, when the European Medicines Agency approved Tafamidis, a TTR stabilizer, for stage I patients (Val30Met and non-Val30Met). To improve upon the pre-existing therapy of liver transplants and given the results of 68% of Tafamidis respondents, other disease-modifying therapeutic approaches were developed: Silencers, Stabilizers, Degraders and Reabsorption agents. In light of these multiple agents clinical trials are the key to improve TTR-FAP treatment.
Objectives: The aim of the analysis is to determine eligibility criteria and optimal timing of patient's enrollment in a clinical trial. Methods: We reviewed the literature using the online database PUBMED. Standard search strategies were applied using the following MESH terms alone or in combination: amyloidosis, transthyretin, liver transplant, tafamidis and clinical trial. Evaluation of the bibliographies was done in order to select relevant articles. Additionally, clinical experience achieved by lead investigators and our own experience was applied in this analysis. Results: Nowadays siRNA (Patisaran®), Antisense Oligonucleotides, Diflunisal and Doxycicline-TUDCA are under clinical trial investigation. Election criteria definition is essential to enroll a patient in one of those clinical trials. Based on the bibliography, inclusion criteria protocols of each clinical trial and our own experience the following criteria have been developed:
1. Stage I to Stage IIIB can be recruited into a clinical trial at any time. 2. Stage I non-respondents to Tafamidis after 12 months treatment who show progression of the disease indicated by.
• Worsening of ambulation (increase of PND score by one point).
• Onset of orthostatic hypotension or impotence.
• Progress of cardiomyopathy with worsening of stage of cardiac insufficiency NYHA by 1 point or of cardiac conduction disorders. 3. It is expected than in the short future OLT patients who underwent illness progression would be enrolled in a clinical trial. Conclusions: Disease staging, tafamidis response and OLT limitations are the main factors to be considered before recruiting a patient for a clinical trial.
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Preimplantation genetic diagnosis for TTR-FAP in Portugal Filipa Carvalho 1, 2 I6 TTR-FAP: liver transplant vs oral medication. How and when Teresa Coelho Unidade Corino de Andrade, Centro Hospitalar do Porto, Portugal Orphanet Journal of Rare Diseases 2015, 10(Suppl 1):I6
Liver transplant was introduced as a treatment for Familial Amyloid Polyneuropathy (FAP) in 1990 and since then it was demonstrated that the best results are seen with early onset patients with predominant neurologic involvement (typically Val30Met patients), at the first years of symptomatic disease. Complete stabilization of the neuropathy is seen in a significant proportion of patients. However the treatment introduced mortality and morbidity due to the surgical procedure itself, variable from center to center. Tafamidis, a transthyretin (TTR) stabilizer, administered orally, was approved in Europe in 2011 to treat neurologic involvement of stage 1 patients with any TTR mutation. We have limited long term data on the efficacy of this treatment and after starting treatment we need at least 6 to 12 months to evaluate the impact of the drug on disease progression. This means that choosing Tafamidis first, may significantly delay the option for liver transplant, in case of oral treatment failure, impacting the results of surgery. The choice between these options is not easy because we have not yet enough comparable data. Most patients would prefer to avoid or to delay the need for an aggressive treatment, hoping to be part of the group of good responders to oral medication. How much should doctors point to a given option? Oral treatment should be prescribed as soon as patients develop the first symptoms and signs of neuropathy. Patients diagnosed with advanced stage 1 disease with high probability of being refused for liver transplant in one year should be sent directly to surgery. If the waiting time is less than one year the benefit of receiving Tafamidis while waiting must be weighted. Patients with more advanced neurologic disease and/or important cardiac involvement should be considered for clinical trials or for other drug treatments. Transthyretin-related familial amyloid polyneuropathy (TTR-FAP) is a rare, autosomal-dominant, adult-onset, systemic disease caused by mutations in the transthyretin (TTR) gene that lead the TTR protein to misfold and deposit as insoluble amyloid fibrils in peripheral and autonomic nerves, the heart, and other organs. [1, 2] . Initial clinical symptoms may appear between the second and ninth decade of life and, without treatment, TTR-FAP leads to death on average within 10 years of symptom onset . [1, 2] . The disease can be difficult to recognize due to extreme phenotypic heterogeneity and nonspecific clinical symptoms. Regular clinical surveillance for detection of first signs and symptoms of TTR-FAP in carriers should focus on clinical, neurophysiological and cardiological approaches. Neurological involvement should be assessed by a careful clinical history looking for positive, negative sensory and motor signs and symptoms as well autonomic complaints. The use of validated clinical scales (NIS, Utah, CAD, Compass 31) and a complete small and large fibers neurophysiological evaluation should be done every year although frequency of visits should be determined on a case-by-case basis depending on clinical. Asymtomatic carriers should be evaluated once an year and symptomatic carriers under needs a closer follow-up every 6 months. Detection of such early sign and symptoms in asymptomatic carriers establishes a diagnosis of TTR-FAP, and anti-amyloid treatment should be promptly initiated. In symptomatic patients under therapeutics a regular follow-up allows a longitudinal evaluation to reflect the maintenance of therapeutic efficacy. Background: Liver transplantation (LTx), introduced in 1990, has served as the only available treatment with capacity to halt the progress of disease in transthyretin amyloidosis. For the most common variant, Val30Met, the effect of a new liver is well known leading to stabilization in the majority of patients. However, not all patients are helped by transplantation. Progress of cardiac amyloidosis is not uncommon necessitating both liver and heart transplantation (LTx/HTx). The effect of LTx is less well studied in patients with non-Val30Met mutations, and outcome has generally been inferior to that seen in patients with the Val30Met mutation. Large variations in survival, not only between different mutations but also between mutations with similar phenotypes, have been noted and it is clear that each mutation needs to be considered individually. Some mutations have similar long-term survival as the Val30Met, while LTx is not to be recommended for other mutations. Several novel pharmaco-therapeutical approaches have emerged over the last years and may provide a more attractive and less invasive treatment for this patient population. Methods: Data concerning outcome after LTx for ATTR amyloidosis was extracted from the FAPWTR registry. Survival rates were analyzed by the Kaplan-Meier method and Log-Rank test. Results: In total, 58 different mutations were treated by LTx alone or by LTX/ HTx. Data from more than 2000 patients were accumulated from 77 collaborating liver transplant centers. Overall, 20-year survival after LTx was 55.3%. Modified Body Mass Index, early onset of the disease, disease duration before transplantation and Val30Met versus non Val30Met mutations were independent significant survival factors. Cardiovascular death was markedly more common than that observed in patients undergoing LTx for end stage liver disease. There has been a significant drop in the annual number of transplants over the last years following the introduction of pharmacotherapy in Europe. A careful evaluation regarding the effect of new promising pharmacotherapies in relation to LTx is of the outmost importance. There is a risk, that patients not responding to pharmacotherapy may be exposed to a less favorable surgical outcome because LTx is delayed. Furthermore, it is unknown if patients not responding to LTx will respond better to alternative treatment and vice versa. Conclusion: Long-term survival after LTx for many TTR variants is excellent. Several new promising pharmacological treatments are under evaluation. In order to determine the most optimal use, these pharmacotherapeutical approaches must be compared to the existing surgical therapy. Perhaps the best treatment for some patients will be a combination of pharmacotherapy and surgery. intra-ocular amyloid deposition observed in patients submitted to liver transplantation. The incidence of ophthalmic manifestations related to FAP depends on mutation involved, geographical area of patient and time of evolution of the disease. More than 100 mutations of TTR have been described but the most frequent in Portugal is TTR Val30Met. Even the same population with the same mutation can present significant clinical variability. TTR Met30Val FAP patients have different phenotypes according to their age at onset of the disease. Methods: Dry eye, abnormal conjunctival vessels, pupillary abnormalities, vitreous opacities and glaucoma are common ocular changes associated to FAP. All are described as well as their etiology and incidence. Clinical cases with demographic data, TTR mutation involved, age at beginning of disease, period of evolution of disease, previous liver transplant or medical treatment, specific ophthalmologic alterations related to FAP and previous ocular surgeries are presented. Results: The most specific ocular manifestations of ATTR-FAP are deposits on lens anterior capsule and pupillary border, scalloped pupil and vitreous amyloidosis and the most severe one is glaucoma. Amyloid deposits on anterior lens surface are central, disciform opacities with more dense border. Amyloid deposits on pupillary border are irregularities of white membranous material. Scalloped pupil, an irregular outlines and fringed edges of pupil, is pathognomonic of ATTR-FAP. Peculiar vitreous opacities are the most common specific change of late onset TTR Met30Val population. There are four types of amyloid vitreous opacities: pseudopodia lentis, fibrils, spherical opacities and pre-vascular opacities. Pseudopodia lentis and typical fibrils, since numerous and dense, are also pathognomonic. Dry eye is a common ocular change in FAP but a non specific. Signs of keratoconjunctivitis sicca like diminution of Break Up Time and punctata epitheliopathy are frequent and complications like corneal neovascularization or opacity and neurotrophic corneal ulcer are unusual. Abnormal conjunctival vessels are a non specific modification of shape of vessels. Pupillary reflex changes, light pupillary hiporreactivity or redilatation lag without loss of light reflex response, can be observed. Glaucoma related to ATTR-FAP is an agressive secondary open angle glaucoma. Frequently, surgery is required (trabeculectomy or valve implants). Glaucoma leads to blindness if left untreated. Amyloid retinal microangiopathy with peripheral retinal ischemia is a rare manifestation. It can be observed in advanced stage of disease. Conclusion: Frequently, the severity of ocular symptoms does not correlate with systemic symptoms, particularly in late onset disease. Vitreous opacities can be the first manifestation of the disease in older patients. Ocular manifestations are common in FAP TTR Val30Met patients and might be potentially severe with visual impairment like vitreous opacities and glaucoma. The most frequent specific alterations observed in early onset cases are signs related to dry eye and in late onset cases, vitreous opacities. Vitrectomy is frequently required to remove amyloid in vitreous cavity to regain vision. In isolated cases with later onset and milder symptoms of the disease, vitreous opacities are frequently the first symptom. Ophthalmologist has an important role in follow-up of FAP patients to accurately treat sight-threatening manifestations and to diagnosis new cases, particularly in late onset TTR Met30Val.
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Imaging cardiac ATTR amyloid Philip N Hawkins National Amyloidosis Centre, UCL, London, UK Orphanet Journal of Rare Diseases 2015, 10(Suppl 1):I10
The heart is the principal site of involvement in non-hereditary ATTR amyloidosis and a major driver of treatment options and prognosis in hereditary forms of the disease. The goals of cardiac imaging in amyloidosis are to aid diagnosis, provide prognostic information, track disease progression and evaluate response to therapy. Echocardiography has long been the mainstay of cardiac evaluation in amyloidosis, particularly that of diastolic dysfunction, but its precision is limited and both inter and intra-observer variability constrain its capacity to detect changes. The recent refinement of myocardial strain imaging provides more reproducible and more sensitive evaluation of systolic impairment, which may be overlooked in amyloidosis, and the longitudinal strain pattern of relative apical sparing strongly supports diagnosis of amyloidosis. Two investigations that are transforming our understanding of cardiac amyloidosis are bone scintigraphy and cardiovascular magnetic resonance (CMR). CMR with gadolinium contrast has proved to be invaluable for identification of cardiac amyloid, showing characteristic patterns of global subendocardial and transmural late gadolinium enhancement associated with abnormal myocardial and blood pool kinetics. The recent refinement of phase-sensitive inversion recovery sequence is highly sensitive and specific, producing findings that are virtually pathognomonic for amyloid. CMR is inferior to echocardiography for evaluating diastolic function but can assess the heart's structure and systolic function with greater accuracy and precision. A key advantage of CMR is its unique ability to give insight about tissue composition through myocardial tissue characterization. T1 mapping studies can quantify the massive expansion of the extracellular space caused by amyloid deposition as well as evaluating the myocyte response to it, i.e. associated hypertrophy or cell loss. The ability to independently track changes in amyloid load and myocardial cell mass will be invaluable in assessing new therapies. One significant limitation of CMR is its incompatibility with most implanted pacemakers and ICDs, an issue that may be addressed by the development of dynamic equilibrium CT, in which gated five minute contrast-enhanced scans have shown excellent potential for diagnosis and quantification of cardiac amyloid. It has been known for decades that bone scintigraphy tracers can localize to cardiac amyloid deposits, but the enormous potential of this tool has only been fully realized in recent years. Studies have confirmed that 99m Tc-3, 3-diphosphono-1, 2-propanodicarboxylic acid (DPD) localizes to the heart in patients with cardiac ATTR amyloidosis with incredible sensitivity and high specificity. The mechanism remains unknown, but virtually all patients with clinically significant cardiac ATTR amyloidosis show Grade 2 or greater localization to the heart using the simple Perugini Grade 1-3 scoring system. Indeed, scans in apparently healthy individuals who have undergone predictive genetic testing for hereditary ATTR amyloidosis have shown that Grade 1 DPD uptake occurs before symptoms or abnormalities on echo or CMR have developed, reflecting the earliest evidence of cardiac ATTR amyloid. DPD scintigraphy is not completely specific for ATTR amyloid in that positive scans occur in a small proportion of patients with (usually very advanced) cardiac AL amyloidosis and some other very rare types, but Grade 2 or 3 cardiac uptake in the presence of a consistent echo and/or CMR and in the absence of a monoclonal gammopathy is in practice sufficient to make a non-invasive diagnosis of cardiac ATTR amyloidosis.
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The landscape of treatment of chronic kidney disease in hereditary ATTR amyloidosis Luisa Lobato 1,2 Hereditary transthyretin amyloidosis (ATTR) is an autosomal dominant disease, caused by mutations in the TTR gene, the most prevalent being V30M. Although each TTR variant has a different involvement, peripheral neuropathy and cardiomyopathy are predominant. Kidney deposits are well recognized since the original description of the disease as well as a renal phenotype is also likely. Kidney involvement with proteinuria and progressive renal failure is a major cause of morbidity and mortality in ATTR amyloidosis. However, kidney impairment is not as common as in AA or AL amyloidosis. Epidemiological studies from Portugal and Sweden reveal that approximately one third of the patients display varying degrees of albuminuria and renal dysfunction. Dialysis improves the prognosis and survival, but morbidity and mortality are higher than in other populations given this treatment. The low level of proteinuria or slight renal impairment does not suppose a so heavy glomerular and vascular deposition of amyloid as in ATTR, particularly in V30M mutation. Moreover, severity of renal amyloid deposition did not consistently parallel that of myelinated nerve fiber loss, with dissociation between kidney and neurological involvement. These are pitfalls that motive troublesome criteria for therapy in ATTR nephropathy. Twenty five years ago, liver transplantation (LT) was introduced as a treatment of ATTR, since this suppresses the production of circulating mutant TTR and theoretically stops the amyloid formation and disease progression, but uncertainties remain about its role on kidney deposits. Renal dysfunction pre LT and acute renal injury post LT are risk factors for chronic renal disease development after LT. The approach for stage 4 or 5 kidney disease remains the combined or sequential liver-kidney transplantation in eligible patients. However, in the majority of patients, hemodialysis is the unique option even in the presence of a well-functioning liver graft. Tafamidis, a TTR stabilizing drug, was described as having a benefit effect on albuminuria and renal function. Non-steroidal anti-inflammatory drugs showed efficacy stabilizing ATTR in early forms of amyloid neuropathy. However, studies with diflunisal noted decline in eGFR even with exclusion of patients with significant renal impairment. RNA interference (RNAi) is an endogenous cellular mechanism for controlling gene expression with application to ATTR neuropathy. The therapeutic value in kidney disease with successfully silenced intraglomerular genes in mouse models was proved, raising the possibility of a future role for renal ATTR amyloidosis. Antisense oligonucleotides are also under clinical trials; renal epithelial cells efficiently take up oligonucleotides without apparent degradation, rendering the kidney an excellent target for site-directed antisense therapy, but also a site of antisense toxicity. Other several natural products that inhibit TTR amyloid fibril formation where progressively investigated to stop neuropathy, but the specificity for renal disease was never evaluated. Until now, doubts remain about the role of new therapies in nephropathy, if there are preferential indications for a specific one and if dialysis patients should be included in a particular treatment.
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Do we need to demonstrate Amyloid in tissue? Laurent Magy Service et Laboratoire de Neurologie, Centre de Référence "Neuropathies Périphériques Rares", CHU Limoges, France Orphanet Journal of Rare Diseases 2015, 10(Suppl 1):I13 Background: Famililal amyloid polyneuropathy due to mutations in the Transthyretin gene (TTR FAP) is a constantly disabling condition leading to death from cardiac or renal failure, or cachexia linked to end-stage neuropathy with autonomic involvement. It has an autosomal dominant inheritance and according to the literature, the phenotypic presentation has a bimodal age of onset with early onset cases occurring before 50 years of age and so-called late onset cases occurring thereafter. To date, therapeutic options are proposed to people who carry a TTR mutation and have evidence of organ involvement. Additional histopathologic demonstration of amyloid deposits in a tissue sample is often considered mandatory to start treatment, although this relies more on professional agreement than on medical or scientific evidence. Methods: We reviewed the literature (PubMed Search and personal files) on TTR FAP with an emphasis on the requirements for amyloid deposit demonstration for its diagnosis in individuals with or without previous evidence of a mutation in the TTR gene. Additionally, we looked for available evidence for amyloid deposit demonstration in TTR mutation carriers before initiating treatment. Finally, we reviewed the diagnostic tools that are available to detect any meaningful change in the peripheral (autonomic and somatic) nervous system in patients at risk for peripheral neuropathy, especially in TTR mutation carriers. Results: The diagnosis of TTR FAP in patients with an apparently sporadic peripheral neuropathy is said to require the presence of a mutation in the TTR gene AND evidence of amyloid deposit in at least one of the following tissues: labial salivary gland, abdominal fat aspirate, gastrointestinal tract and (sural) nerve. However, we found surprisingly low scientific evidence to support the mandatory demonstration of amyloid in any tissue in individual with peripheral neuropathy AND TTR mutation after excluding any other possible cause of neuropathy. This issue is very important in the genetic era because we are increasingly aware of "asymptomatic" TTR mutation carriers and there is still no consensus on the adequate follow-up for these patients (in terms of timing and investigations tools). We found a wide variety of available tools to detect somatic and autonomic peripheral neuropathy in TTR mutation carriers. Based on the available literature, some proposals may be done in order to diagnose as early as possible peripheral neuropathy in these individuals. Conclusion: Available literature shows that the need for demonstration of amyloid deposit in any tissue in patients with peripheral neuropathy and a mutation in the TTR gene is more a dogma than an evidencebased requirement. Although search for amyloid deposits should be conducted when amyloid neuropathy is suspected, we think people who carry a TTR FAP mutation and have reasonable evidence of peripheral neuropathy should not be denied access to effective therapy, even if no demonstration of amyloid deposit can be done.
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Emerging CNS involvement in FAP-TTR long survival patients Luisa Maia Neurology Department, Hospital Santo António -CHP, 4099-001 Porto, Portugal Orphanet Journal of Rare Diseases 2015, 10(Suppl 1):I14 Background: Transthyretin-related amyloidosis (ATTR) are the most common hereditary forms of amyloidosis and Familial Amyloid Polyneuropathy (FAP) with the TTR V30M mutation, also designated as ATTR-V30M, is the most frequent form. Up until recently, despite TTR deposition in the CNS of FAP patients at a meningeal-vascular location, clinically relevant presentations were rarely recognized. Methods: We evaluated a series of consecutive liver transplanted patients (ATTR-V30M and non-ATTR) for the presence and type of focal neurological episodes due to CNS dysfunction (FNEs). We characterized brain neuroimaging (CT scan) in patients presenting FNEs and transthyretin amyloid deposition in the brains of ATTR-V30M autopsied patients. Results: We found that CNS clinical involvement occurs in FAP patients that underwent liver transplantation (LT). Patients exhibited positive and negative FNEs clinically similar to the recently described "amyloid spells" characteristic of Aβ related cerebral amyloid angiopathy (CAA) patients. Longer disease duration, male gender and renal dysfunction were associated with the presence of FNEs in FAP patients after LT. In postmortem brain analysis, FAP patients exhibit prominent CAA associated to progressive TTR meningeal-vascular deposition, that progressed from the meninges and its vessels towards meningo-cortical vessels and the superficial brain parenchyma, as disease duration increased. Neuroimaging findings (lobar brain hemorrhage, localized subarachnoid hemorrhage and white matter damage) also support that TTR related CAA contributes to this new clinical phenotype. Conclusions: Both the clinic presentation and the topography of the neuropathological abnormalities of FAP patients with this new CNS phenotype overlaps to what is known to occur in sporadic Aβ-associated CAA. Moreover, neuroimaging findings in such patients suggest that CAA may be a leading player, hinting that these two pathologies could also share devastating consequences (brain hemorrhage, localized subarachnoid hemorrhage and, eventually, cognitive decline). Given the hemorrhagic risk of these vasculopathies, our results have implications in the treatment and clinical follow-up of FAP patients. In addition, sensitive imaging methods (e.g. MRI) need to be implemented in the study of ATTR patients presenting FNEs. Present and future disease modifying therapies should consider CNS TTR deposition as a target.
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Biopsy experience in a FAP endemic area Manuel Melo Pires Neuropathology Unit, Hospital Santo António / Centro Hospitalar do Porto, Porto, Portugal Orphanet Journal of Rare Diseases 2015, 10(Suppl 1):I15 Background: Over a thousand nerve, skin and salivary gland biopsies were performed in FAP patients during the last forty years in our centre. We will try to demonstrate the different biopsy approaches over the years and confirm that biopsy of different types of tissue are useful not just in the diagnosis but also in the study of the pathogenesis of the disease. Methods: Retrospective analysis of our database since 1973 till 2014 showed 253 nerve biopsies, 441 skin and 738 salivary gland biopsies. Some of these were combined biopsies, nerve and skin or muscle nerve and skin. Except for the salivary gland biopsies they were all performed by one of our neuropathologists. Results: Until 1988, nerve and skin biopsies were commonly performed for diagnostic purposes, after that with genetic testing being available all tissue biopsies declined in number and were only needed in difficult diagnostic cases or when genetic testing was not available. Nerve biopsy became relevant again with the appearance of atypical clinical presentations or late onset or sporadic patients where the clinical diagnosis of FAP had not been considered. Nerve biopsy was also performed to establish the diagnosis of "de novo" amyloid neuropathy in recipients of domino liver transplants from FAP individuals, who started showing symptoms of neuropathy, and to rule out other causes of neuropathy. Since 2005, salivary gland biopsy has become our method of choice to demonstrate amyloid and is as effective as nerve or skin biopsies. Conclusions: During the last forty years biopsies of different tissues were used to demonstrate amyloid. Nerve biopsy is still a useful tool not just for diagnostic purposes in problematic cases but also to understand the pathogenesis of the disease. Salivary gland biopsy is now our favoured method as it is a minimally invasive procedure and amyloid is demonstrated in very early stages of the disease. Biopsy could also be a tool to monitor treatment with the new drugs available. In the last decade, the availability of the cardiac biomarkers N terminal pronatriuretic peptide type-B (NT-proBNP) and troponins has radically changed the approach to diagnosis, staging, and response assessment of cardiac amyloidosis. Despite similar appearance at standard imaging, the main types of amyloidosis involving the heart are characterized by different rates of progression and different outcomes. In general, patients with ATTRm amyloidosis have lower concentrations of cardiac biomarkers and usually a better prognosis than subjects suffering from AL amyloidosis.
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Nevertheless, the clinical manifestations of ATTRm amyloidosis are heterogeneous. Different amyloidogenic TTR mutations give rise to different cardiac phenotypes, ranging from exclusively neuropathic diseases, through mixed phenotypes, to mutation characterized by severe cardiac dysfunction. For instance, one of the mutations associated with cardiac involvement in ATTRm amyloidosis, Ile68Leu, presents with high NT-proBNP concentrations, comparable to those observed in patients with cardiac AL amyloidosis. In our series, survival of patients with Ile68Leu ATTRm is not different from that of cardiac AL patients. Thus, it is possible that NT-proBNP represents a viable marker for early diagnosis of cardiac involvement in ATTR patients with "aggressive" mutations. This marker could be considered in the screening of carriers of these mutations. Despite the lack of systematic studies of cardiac biomarkers in ATTR amyloidosis, the results of several small published series and the analysis of the Pavia patient population, indicate that NT-proBNP and cardiac troponins have prognostic value in this disease, correlating to amyloid burden and adding to known prognostic factors. The availability of several novel therapeutic options for ATTRm, require objective means for the assessment of treatment efficacy in routine clinical practice and in clinical trials. Early results from the Pavia series indicate that NT-proBNP progression portends a poor prognosis, and cardiac biomarkers will probably find their place in the evaluation of response to therapy in ATTRm amyloidosis. Cardiac biomarkers will most likely become increasingly useful in the management of patients with ATTRm amyloidosis in the near future. However, studies of biomarkers in this disease are hindered by small numbers and disease heterogeneity. Prospective studies and international collaboration are warranted to define the role of cardiac biomarkers in the diagnosis and follow-up of cardiac ATTRm amyloidosis.
Background: In systemic amyloidosis, disease is caused by extracellular accumulation of amyloid fibrils which, unlike other interstitial debris, are not cleared and which disrupt tissue structure and function. Direct removal of amyloid deposits is required to preserve and possibly restore tissue and organ function. We are targeting serum amyloid P component (SAP) for this purpose. SAP normal plasma protein is a normal plasma protein which binds to all amyloid fibrils and is thus always present in all human amyloid deposits. Administration of hexanoyl bis(D-proline) (CPHPC) swiftly depletes circulating SAP but leaves some SAP in amyloid deposits as an amyloid-specific antigen target. In human SAP transgenic mice with systemic AA amyloidosis, CPHPC treatment, to deplete human SAP from the plasma, followed by a single dose of anti-human SAP antibodies produced swift, almost complete, clearance of visceral amyloid (Bodin et al. Nature, 2010; 468:93-7) . In a mouse SAA transgenic systemic amyloidosis model, which uniquely includes cardiac amyloid, a second dose of anti-SAP antibody, after the first dose had eliminated massive liver and spleen deposits, significantly removed amyloid from the heart (Simons et al. Proc Natl Acad Sci USA. 2013; 110:16115-20) . Amyloid clearance by anti-SAP antibody required classical complement pathway activation and macrophages. Amyloid destruction was mediated by multinucleated giant cells (MGCs), formed by macrophage fusion. MGCs have abundant surface membrane ruffles, enabling the engulfment of very large complement opsonised amyloid targets which were then swiftly destroyed within phagolysosomes. Amyloid clearance was maximal by 14 days. No ill effects were detected. After licensing this new treatment in February 2009, GlaxoSmithKline (GSK) fully humanised our optimal mouse monoclonal anti-SAP antibody and prepared for the first in human clinical study that started in June 2013. We have lately reported that a single dose of humanized monoclonal anti-SAP antibody, following depletion of circulating SAP by CPHPC, substantially reduced the amyloid load, especially from the liver, in patients with systemic AL, Fifty years ago, the focus on the Val30Met type of the disease, in which neurologic manifestations predominate, led to the widespread notion that hereditary transthyretin-related amyloidosis (ATTR) was essentially a neurologic disease. It is now clear that ATTR is extremely heterogeneous on both genotypic and phenotypic grounds. The clinical spectrum of the disease ranges from an almost exclusive neurologic involvement to strictly cardiac manifestations. This heterogeneity is linked to several factors including specific transthyretin mutations, geographic distribution and endemic vs. non-endemic aggregation type. The existence of exclusively or predominantly cardiac phenotypes makes the recognition of the disease very challenging since it can mimic other more common causes of left ventricular "hypertrophy". Assessment of such patients should include an active search for possible red flags that can indicate the correct final diagnosis. More in general the clinician must be aware that:
• Cardiac amyloidosis (CA) should be suspected in any patient with heart failure, unexplained increased LV wall thickness and nonincreased end systolic left ventricular volume.
• In a patient with an initial diagnosis of hypertrophic cardiomyopathy (HCM), look for the infiltrative phenotype hidden beneath the hypertrophic one!.
• A distinctive sign of CA is the abnormal ratio between left ventricular thickness and QRS voltages rather than low QRS voltages, alone. The absence of low QRS voltages doesn't rule out a CA if the context is otherwise fitting and up to 20% of subjects with CA can have electrocardiographic evidence of left ventricular hypertrophy.
• In an elderly man with unexplained concentric left ventricular hypertrophy, especially in the absence of hypertension, always consider the possibility of wtTTR CA!.
• Amyloidotic cardiomyopathy in an elderly patient with monoclonal gammopathy is not necessarily related to AL: consider the possibility of wTTR + MGUS.
• Longitudinal LV function can be severely depressed despite a normal LVEF and the myocardial contraction fraction is often low suggesting reduced global myocardial shortening.
• Myocardial deformation is reduced in amyloidotic cardiomiopathy but the apex is generally spared.
• In CA, Gadolinium distribution at MRI is heterogeneous: subendocardial late gadolinium enhancement (LGE) is not the only diagnostic pattern and the absence of LGE does not exclude CA.
• Bilateral carpal tunnel syndrome in a man with HCM-like phenotype on echo is highly suggestive of TTR-related CA.
The natural history of ATTR is only partially known, due to the rarity of the disease and its high genotypic heterogeneity. Patients with ATTR cardiomyopathy have a much more indolent course than those with AL etiology. Progression of neurological disease and heart failure are the leading causes of death. As in AL amyloidosis, in ATTR the presence of cardiac involvement is an incremental risk factor for overall and cardiovascular events. Consequently, non-Val30Met mutations, in which cardiac involvement is more frequent and severe, appear to be associated with a particularly poor prognosis, even after successful OLT . Very little is known about the underlying cause and the incidence of sudden death, which has been reported to be associated with the occurrence of advanced atrioventricular blocks, ventricular tachycardia/ fibrillation, or, probably more frequently, electromechanical dissociation.
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TTR amyloidosis: a scientific journey since Andrade Maria João Saraiva 1,2 Mário Corino de Andrade described in 1952 in the journal "Brain" the first form of an hereditary amyloidosis, Famlial Amyloidotic Polyneuropathy, FAP -affecting the peripheral nervous system, also known as Andrade´s disease. In 1939 Andrade observed different patients complaining of loss of sensitivity to temperature and pain. These symptoms affected other families in the area, namely fisherman who complained of loss of sensitivity in their feet when touching the ropes of their small fishing boats. Andrade with the extraordinary intuition that all collaborators admired, realized the clinical symptoms deviated from what he had seen until then. Andrade suspected he was in the presence of a rare hereditary disease. To understand in depth what he considered new, he asked the collaboration of experts in different fields, like genetics, pathology, confirming the genetic nature of the disease and the presence of systemic amyloid deposits, particularly in the peripheral nervous system. Since this seminal work, the explosion of molecular biology tools gave us today perspectives for therapies. Some of the concepts and hypotheses put forward then with basic equipment and techniques available in the last century evolved tremendously giving us molecular and cellular in-depth knowledge; Andrade´s vision is still updated but need urgent clarification if we want to move towards urgent efficiency therapies of the disease. This lecture will exemplify one case where we still stand behind a black box despite access to modern know-how. and increases personal control; (5) choose the course of action that seems appropriate to them and act in accordance with that decision; and (6) make the best possible adjustment to the disease or the genetic risks (modified by EuroGentest Unit 3 from Frazer, AJHG 1974; Biesecker & Peters, AJMG 2001; Harper, 2012) . Guidelines: Genetic counselling must always begin with the establishment or documentation of a clinical and genetic diagnosis in a proband, followed by counselling of relatives at risk. In the context of presymptomatic testing (PST), i.e., in healthy relatives at high-risk for a late-onset monogenic disease with high penetrance, as ATTR amyloidosis, a protocol of pre-and post-test genetic counselling needs to be offered; and be accompanied by psychosocial evaluation and support, their purpose being to assess motivations for testing, explore decision-making processes, test coping mechanisms, predict risk of adverse emotional reactions, prepare psychosocial support, identify values and family dynamics and reinforce social support networks. Family's experience (late vs. early-onset) is critical. PST should begin with relatives at higher risk (cascade testing). Minors should not be tested, as they might lose their autonomy and suffer discrimination. In the context of diagnostic testing, neurological symptoms must be evident, so that the genetic laboratory does not perform an inadvertent PST. In the context of prenatal diagnosis (PND) or of preimplantation genetic diagnosis (PGD), both parents must be involved in the counselling protocol, one of them must be affected or a presymptomatic carrier, with a TTR mutation previously identified in the family; in addition, for PND, there must be a clear motivation for termination of pregnancy if the foetus is a mutation carrier. Conclusions: Availability of therapies and ongoing clinical trials may be a (false) motivation for increased adherence to PST; however, this is not relevant for treatment (will change when preventive measures or presymptomatic treatment become possible). ATTR amyloidosis, though potentially treatable, is still currently incurable (mutation is always present and heritable). Genetic counselling is always mandatory. TTR familial amyloidosis is a systemic disease, with a frequent cardiac involvement. For clinical reasonsrelated to its prolonged latency -and historical reasonsas the first cases where diagnosed by neurologists, in young patients who died from neurological disease before cardiac complications occurred-familial cardiac amyloidosis (TTR-FAC) has been and still remains underestimated. It is known to be responsible of 40% of midterm deaths after liver transplantation. TTR-FAC appears irreversible; it can progress after liver transplantation, and is associated with a poor prognosis. Hence the heart deserves a special attention when taking in charge patients with familial amyloidosis, especially since there are several new promising therapeutic options. When following patients with a TTR mutation, the occurrence of a cardiac disease can be anticipated considering gene mutation (opposing the so called cardiac vs neurologic mutations), family history, and age, but as it can be observed in all types of mutations, with various frequencies, it can never be ruled out beforehand. The initial workup of those patients should take into account: -Cardiac infiltration, responsible for restrictive cardiomyopathy, detected by clinical examination, assessment of cardiac capacity with a 6 mn walk test, ECG (microvoltage), echocardiography with typical thickened sparkling myocardium, decrease of longitudinal systolic deformation (strain), and biomarkers (NT pro BNP, troponin). Early detection of amyloid deposits can be obtained by MRI (T1 mapping) and bisphosphonate scintigraphy. Cardiac catheterization and myocardial biopsy are rarely mandatory. -Conduction abnormalities can be responsible of syncope by atrioventricular block. A simple ECG assessment is a good start, and any abnormality (any degree of AV block, bundle branch block) should prompt electrophysiological study. Prophylactic pacemaker implantation is widely used; in our experience it is necessary in about 1/3 of patients during the course of the disease. Malignant arrhythmias (ventricular tachycardia or fibrillation) appear uncommon.
-Cardiac sympathetic and parasympathetic denervation, as assessed by cardiac variability (Holter), atropine challenge, and MIBG scintigraphic imaging, occurs very early, and has a very strong prognostic value.
The initial cardiac assessment of patients with TTR amyloidosis should not be limited to the evaluation of obvious cardiac damage, which is irreversible and can lead to cardiac transplantation in a limited number of patients. All our efforts must be directed to achieve a very early diagnosis of TTR-FAC, which should be taken into account to start the treatment as early as possible. In the era of SiRNA therapy for this rare and deadly disease, the "minimal" cardiac assessment should be performed in specialized reference centers, devoting their efforts to research for very early and accurate diagnosis and development of new therapies, and should by no means be minimal. Systemic amyloidosis related to mutation of TTR gene can be complicated with Familial Amyloid Cardiomyopathy (TTR-FAC), a severe and life threatening form of heart failure with preserved ejection fraction, with a poor prognosis. To date there is no proven effective specific treatment against TTR-FAC, and the usual treatments of chronic heart failure are either ineffective or contra indicated, except for diuretics. Progression of the disease results in reduction of physical capacity, repeated hospitalizations, increase in diuretics dose, and ultimately in refractory heart failure. Cardiac transplantation has been performed in TTR-FAC since 2003, and reported in 40 patients in the literature with acceptable results in highly selected patients. The results of combined heart and liver transplantation appear to be similar or even better than for isolated heart transplantation, due to a "tolerance" phenomenon, with less cardiac rejection and less graft coronary artery disease. We performed heart transplantation for TTR-FAC in 10 pts (9 men; mean age 59 years range 49 to 70), NYHA class II to IV, isolated in 6 and combined with a liver transplantation in 4. Patients had received a pacemaker (n=3) or a defibrillator (n=3) during their preoperative course. Mutations of patients were TYR77 in 5, SER24 in 1, GLU62 in 1, MET30 in 1. In hospital mortality was 40%. Patients can be considered as good candidates to heart transplantation for TTR-FAC if they have symptomatic heart failure persisting under optimal medical therapy, disregarding their ejection fraction, normal pulmonary resistance, no major comorbidities, an acceptable physical and psychological condition, and limited neurologic involvement (ability to engage in a post-operative rehabilitation program is mandatory). In the future, indications of combined heart and liver transplantations will have to be weighed against isolated heart transplantation in association with specific medical treatments (Tafamidis, or SiRNA). most common symptoms are those of early satiety, nausea and vomiting from the upper gastrointestinal (GI) tract, and constipation, constipation alternating with diarrhoea, or continuous diarrhoea from the lower. Faecal incontinence is common in later stages of the disease and has a devastating impact on the patient's quality of life. Evaluation and treatment: Upper endoscopy and scintigraphic visualisation of gastric emptying can diagnose gastric retention often before the patients develop symptoms. For treatment, motilin agonists, such as erythromycin can be used, and though it often increases gastric emptying its symptomatic efficacy is limited. Symptomatic relief can be achieved with dopamine 2 receptor antagonists such as metoclopramide, which, however, has little impact on gastric emptying. Gastric pacing by a gastric pacemaker is effective for symptom relief in diabetes mellitus induced gasroparesis, but with only limited efficacy on gastric emptying. Constipation is a common symptom, and osmotic active preparations (polyethylene glycol) and picosulfate are often effective. Alternating diarrhoea and constipation are often induced by small bowel contamination caused by stagnant content in the small intestine. Small intestine culture or more convenient the hydrogen breath test can disclose the condition, and antibiotics such as tetracycline and/or metronidazole are generally effective, and repeated short courses of treatment can be prescribed when needed. The onset of more continuous diarrhoea is often related to malabsorption, especially of fat and bile acids. Various tests can diagnose the conditions, such as the 75 Se-homocholicacid-taurine (SeHCAT) test, which diagnose bile acid malabsorption, a condition that often accompany fat malabsorption. Bile acid sequestrates and fat restricted diet, with the help of a dietician to ensure sufficient nutritional intake should be tried. Octreotide, a somatostatin analogue has also been reported to be effective. When treatment fails, and the patient has devastating faecal incontinence, a sigmoid stoma can help the patient to gain control of his/hers bowel movements. It is important to give the patients adequate supplementation with fatsoluble vitamins and calcium to avoid osteoporosis, and B12 vitamin supplementation may be needed. Symptoms of adrenal insufficiency can be difficult to distinguish from GI symptoms caused by ATTR amyloidosis. Cortisol supplementation can have a dramatic effect on the patient's symptoms, including those of orthostatic hypotension.
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Therapeutic education programme in TTR-FAP Marie Théaudin 1,2,3* , Cécile Cauquil 1,2 , Teresa Antonini 1,4 , Vincent Algalarrondo 1, 5, 6 Background: The French National Reference centre for Transthyretinrelated amyloidosis (ATTR) was accredited in 2005. One of its 10 lines of action is to inform and educate patients about their disease to improve their care and reduce morbidities. We thus decided to elaborate a therapeutic patient education (TPE) programme, starting with patients' needs assessment. We will describe our needs assessment and discuss our experience in TPE for ATTR patients. Methods: A qualitative research study was conducted with one-to-one semi-structured interviews of selected individuals. Recorded interviews were analysed to identify the skills that patients need to acquire. A TPE programme was elaborated on the basis of these findings. Results: Analysis of the interviews showed that interviewees had a good knowledge of the disease and its symptoms but they had difficulties explaining the disease mechanism and did not have an adequate knowledge of the available treatment options, although they knew that liver transplant might halt progression of the disease. ATTR amyloidosis appeared to have a major negative impact on the patient's physical and mental well-being. Patients feared loss of autonomy and having to require assistance from their relatives and spouses. All interviewees were keen to participate in a TPE programme. Based on this needs assessment, we identified seven skills that patients need to acquire and several pedagogical goals to be achieved during the education programme. An interdisciplinary team then elaborated a complete TPE programme and its educative tools. The programme includes 2 individual sessions (initial educational diagnosis assessment and final assessment of the skills acquired during the programme) and 7 collective sessions. First TPE sessions started in October 2014. To date, 8 patients living close to Paris attended 4 collective TPE sessions. After the sessions, all patients stated they were very satisfied with the quality of the education provided, the educational tools, the timing of the sessions. They all stated the collective sessions met their expectations. Conclusion: Elaboration of a TPE programme for ATTR amyloidosis required to obtain useful information from the patients themselves, and their relatives, concerning their perception of their disease. This needs' assessment constituted the basis for designing the first TPE programme, to our knowledge, for ATTR amyloidosis. Patients who attended the first TPE sessions were very satisfied and felt that the sessions fully met their educational expectations. Further TPE sessions are scheduled within the end of 2015 and we plan to organize TPE sessions in other French cities where ATTR amyloidosis patients are followed.
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Do we need to demonstrate amyloid in tissue for hereditary ATTR amyloidosis ? Per Westermark Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden Orphanet Journal of Rare Diseases 2015, 10(Suppl 1):I25
Amyloidosis is by definition deposition of aggregates of proteins in a characteristic β-pleated sheet fibrillar conformation. Amyloid is recognized by its histological appearance particularly after some specific stainings among which Congo red most commonly is used. A green birefringence is the hallmark of all kinds of amyloid. There is a number of emerging diagnostic techniques based on labelling with antibodies, other proteins and some other ligands that are at least to some degree specific for amyloid and may be used for in vivo detection of amyloid. With some exceptions, such techniques are still not sensitive enough to detect small deposits. Biopsy stained with Congo red and examined in a polarization microscope is necessary presently. Hereditary ATTR amyloidosis constitutes a heterogeneous disease group with varying organ consequences, not only from peripheral nerves and heart. Amyloid staining properties vary and Congo red affinity and birefringence may be very weak, particularly in amyloid consisting of TTR fragments which is common (1) . Therefore is amyloid sometimes difficult to recognize also in biopsies. Given the varying clinical manifestation of ATTR amyloidosis it is my opinion that a histological proof should be obtained if possible. There may be exceptions sometimes depending on local conditions. In endemic areas with one specific TTR mutation, high penetrance and a relative monomorphous presentation of ATTR amyloidosis, diagnosis may sometimes be safe without a histological proof. This may be the case in some areas of Portugal. In most parts of the world, however, cases of systemic amyloidosis are usually scattered and a histological proof should be recommended. The site of biopsy may be discussed. We perform subcutaneous adipose tissue biopsies (surgical or by punch technique) with good results. Fine needle biopsy is not recommended since with this technique very little connective tissue is obtained, which is the site of ATTR amyloid containing TTR fragments (2) . In other centers, labial salivary gland biopsies are preferred. Gastrointestinal tract is another option. A substantial advantage with biopsy techniques is that the biochemical type can be determined directly. A question to discuss is whether indirect techniques such as DPD scintigraphy, SAP scintigraphy or PET with various ligands are safe enough for a definite amyloid diagnosis. Also alternatives to Congo red are under development but not yet validated enough for clinical use.
Background: Familial amyloid polyneuropathy related to transthyretin gene (TTR-FAP) is a life-threatening disease transmitted as an autosomal dominant trait. Val30Met mutation accounts for the majority of the patients with large endemic foci especially in Portugal, Sweden and Japan. However, more than one hundred other mutations have been described worldwide. A great phenotypic variability among patients with late-and early-onset has been reported. Objective: To present a detailed report of TTR-FAP patients diagnosed in our tertiary neuromuscular center, in a 20-year period. Methods: Clinical informations were gathered through the database of our center. Results: The study involved 76 individuals carrying a TTR-FAP mutation. Three phenotypes were identified, each corresponding to a different TTR variant, homogeneous within and heterogeneous between each other: i) Glu89Gln mutation, characterised by 5th to 6th decade onset, neuropathy as presenting symptoms, early heart dysfunction, cardiomyopathy as major cause of mortality followed by dysautonomia and cachexia; ii) Phe64Leu mutation, marked by familiarity reported in one-half of cases, late onset, severe peripheral neuropathy, moderate dysautonomia and mild cardiomyopathy, death for wasting syndrome; iii) Thr49Ala mutation, distinguished by onset in the 5th decade, autonomic disturbances as inaugural symptoms which may remain isolated for many years, moderate polyneuropathy, cachexia as major cause of mortality followed by cardiomyopathy. Conclusions: This survey highlighted a prevalence of 8.8/1,000,000 in Sicily Island. Good knowledge of the natural history of the disease according to different TTR mutations allow clinicians to optimise multiprofessional care for patients and to offer carriers a personalized follow-up to reveal first signs of the disease. Methods: Four mutations have been found in the country so far: Glu89Gln, Ser77Phe, Val30Met, Ser52Pro. Glu89Gln is the most frequent mutation affecting 48 different families. Selective genetic screening program is performed in the affected families. A total of 261 individuals belonging to affected families were examined. All individuals who took part in the screening program signed an informed consent for a voluntarily participation in the program. TTR-FAP mutations were found in 130 individuals: Glu89Gln -107; Val30Met -15; Ser77Phe -5; Ser52Pro -2; compound heterozygous carrier of two mutations: Glu89Gln and Val30Met -1. Results: Most of the FAP families with Glu89Gln mutation are concentrated in two districts of the South-West part of the country on the boundary with Macedonia. We accept this mutation as typical for the Balkan -Mediterranean region with possible founder effect connecting patients with Glu89Gln from neighbouring countries. Ser77Ple is presented in 5 families originating from only one village. In a historical view we do not exclude inserting of this mutation in our population century ago. Val30Met is relatively rare till now in Bulgaria. Most of the patients originate from small focus placed in the south-east part near the border with Greece. Conclusion: Every one of the mutations presents with specific clinical phenotype as: average age of onset, disease course / survival, male / female distribution, first symptomspolyneuropathy, cardiac, gastrointestinal or other involvement, sporadic or familial. The clinical phenotype and the place of origin are helpful for preliminary information for the expected mutation. Background: Familial Amyloid Polyneuropathy (FAP ATTRV30M) is an AD systemic amyloidosis, due to a point mutation in the transthyretin (TTR) gene. Although in Portugal the disease has been characterized by its early onset (lower than 40yrs), a wider age-at-onset (AO) variability has been uncovered. The mean AO is 35.3, but more and more late-onset (higher than 50yrs) cases are being ascertained, often matched with older asymptomatic parents. Our aim now was to look into late-onset cases and aged-asymptomatic carriers in order to unravel familial aggregation of lateonset and to characterize these families regarding their epidemiology. Methods: From the largest registry worldwide with 2754 patients (678 families), we analyzed a group of 326 late-onset cases (133 families) regarding gender and also their transmitting parent. Additionally we analyzed 222 asymptomatic carriers on regular follow-up, aged above 40 at last observation and their first-degree relatives, belonging to 122 families. We performed a descriptive analysis and used the Student's ttest for comparisons between groups. Results: Age-at-onset was 60.03 for men and 59.25 for women (NS), as opposed to the general sample where women had a later onset (37.6) than men (33.4). Familial aggregation of late-onset cases is apparent, with some families having up to 11 late-onset cases. Out of 678 probands,~40% had no affected parent at time of diagnosis, this figure being 86% (115/133) among late-onset probands. These parents had died with no signs of the disease mostly at old-age. No one had an affected parent with early-onset of the disease. For asymptomatic carriers, age-at-last-observation varies between 40 and 49 for 103 subjects and was above 50 for 119 of them. Mean age-at-lastobservation was 54.06 (SD: 12.2; range: 40-89) and no gender differences were found. We were able to identify 92 transmitting-parents (59 fathers, 33 mothers) with know AO. Their mean AO was 56.91 (SD: 12.8; range: 25-80) and no differences in AO were found between parent's gender. Also, we found a mean AO close to 40 years for siblings of these asymptomatic carriers (mean: 39.91; SD: 8.89; range: 24-65). Conclusions: While most of FAP probands had one affected parent (as expected in an AD disease), a significant number has a late-onset and no affected parent at time of diagnosis. We confirmed familial aggregation of late-onset cases. We also found that for late-onset cases no gender differences are observed. This shows that some families are protected from the severe manifestations of FAP. Due to these different clinical aspects of FAP in late-onset patients it is crucial to explore mechanisms that can be related with aging and protective factors that can lead to new therapeutic strategies.
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The hidden story behind gender differences in familial amyloid polyneuropathy (FAP) ATTRV30M Diana Santos 1* , Teresa Coelho 2 , Miguel Alves-Ferreira 1 , Jorge Sequeiros 1 , Isabel Alonso 1 , Manuela Grazina 3 , Alda Sousa 1 , Carolina Lemos 1 Background: Familial amyloid polyneuropathy (FAP ATTRV30M) is an autosomal dominant systemic amyloidosis, due to a point mutation in the transthyretin (TTR) gene (chr18q12.1). The most frequent one, V30M is associated with several clusters. Among Portuguese families, FAP shows a wide variation in in age-at-onset (AO) [19-82 yrs] and this variability is also apparent between generations. Also, significant differences in AO regarding gender are known in Portuguese series, where women were found to have a later-onset than men. Moreover, mother-son pairs showed larger anticipation (> 10 yrs) while the father-daughter pairs only showed residual anticipation. Therefore, to unravel these gender-related differences in AO, we studied three candidate-genes (AR, HSD17B1 and BGN) linked to sexsteroid hormones or X-linked as genetic modifiers of AO. We also evaluated if mitochondrial DNA (mtDNA) copy number is associated with AO. Methods: We analysed a DNA sample of 318 Portuguese patients (106 families) corresponding to 152 males and 166 females. Additionally, asymptomatic carriers and non-carriers were also included in the study. Polymorphisms in candidate genes were genotyped by several standard techniques and mtDNA copy number was assessed using appropriate software for analysis. Results: Our patients' sample shows a mean AO of around 39 years, but mean AO in males (37.28) is lower than in females (40.52), as already described in the literature. Moreover, we found some polymorphisms significantly associated with AO variation. For the AR gene, in the male group, three polymorphisms were associated with an early AO, while in the female group, four were associated with both an early and later AO. Regarding parental transmission in this gene, for rs5919392, we found that e affected mothers transmitted the T allele more often than expected (which is associated with an early-onset). For HSD17B1 gene, we did not find any significant results. Concerning BGN gene, in the male group no significant results were found associated with AO but, in the female group, one polymorphism was associated with a later AO. Regarding mtDNA copy number, there are significant gender differences when we compared controls and patients groups. Patients present an mtDNA copy number higher than controls. We also found significant differences in the female group when we compared late and early patients. Conclusions: This study revealed for the first time the contribution of the AR and BGN genes as AO modifiers both in males and females. Moreover, it was important to show that mtDNA copy number is associated with FAP. Therefore, we showed that FAP expresses differently in males and females. These results are significant to improve clinical management, with important implications in genetic counselling and therapeutic strategies. Background: Only a few patients and families with transthyretin associated familial amyloid polyneuropathy (TTR-FAP) have been described by different authors in Israel. The objective of this study was to elucidate the natural history, clinical manifestations, electrophysiological features, ethnic origin and genetic findings of all the known patients with TTR-FAP in Israel. Methods: We reviewed the medical records of all the patients that have been reported and those who have not yet been described. We retrospectively assessed the major clinical, laboratory and genetic findings of the patients. Results: Seventeen patients were studied. All were Jews. Eleven were of Yemenite descent, harboring the ser77tyr mutation. Of these, seven belonged to a large 3-generation family, and each of the other four to different unrelated families. Three patients were Ashkenazi; one carried the val30met mutation, another the phe33leu mutation, and the third had two mutations on one allele: phe33Ile and gly6ser. Two patients were of Iranian origin showing val32ala mutation, and one of Tunisian origin showing the val30met mutation. Onset in most patients was in the sixth decade, presenting with sensory loss of the lower and upper limbs. About half of the patients experienced at onset pain, autonomic nervous system manifestations and demonstrated evidence of amyloid cardiomyopathy. One patient of Yemenite descent presented with amyloid cardiomyopathy without neuropathic features. Nerve conduction studies showed sensorimotor axonal neuropathy in all. Sural nerve biopsies were obtained in eight patients; two biopsies did not reveal amyloid deposit. The average course was rapid, and most patients died within 4-7 years. The cause of death was intestinal malabsorption and cardiomyopathy. Two patients of Yemenite origin underwent liver transplantation, which slowed down the disease progression. Conclusion: TTR-FAP exists in the Israeli population and is disproportionately common among Yemenite Jews. The worldwide common mutation val30met is rare. The presence of other mutations may explain the relatively rapid course of the disease in the Israeli patients.
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Familial amyloidotic polyneuropathy in Crete, Greece Minas Tzagournissakis 1* , Cleanthe Spanaki 1 , Georgios Amoiridis 1 , Demetrios Samonakis 2 , Andreas Plaitakis 1 , Panayiotis Mitsias 1 Background: Familial amyloidotic polyneuropathy (FAP) has been related to more than 100 transthyretin (TTR) gene mutations. The disease has been reported among different ethnic groups including some kindreds of Greek origin. Here we report the clinical and molecular data, as well as treatment outcome of all Cretan patients with FAP seen at the University Hospital of Heraklion-Crete. Methods: Seventeen patients (8 men and 9 women), members of 6 unrelated families originating from 4 different foci on the island were studied. All had a positive family history for polyneuropathy. Extended pedigrees spanning 5 generations were constructed. All patients underwent thorough clinical and laboratory investigation including rectal and/or nerve biopsy as well as molecular analysis. Results: The mean age of disease onset was 30 years (range: 27 to 43). All patients presented with paresthesias, temperature loss and progressive weakness at the lower extremities, urinary difficulties, diarrhea, postural dizziness and weight loss. The upper extremities were involved later during the disease progression. Neurological examination revealed loss of pain and temperature sensation in a glove and stocking distribution and distal weakness. All but two exhibited orthostatic hypotension. Four patients presented with carpal tunnel syndrome. Although cardiac arrhythmia was a common symptom to most patients, heart failure developed in 3 patients during the late phase of the disease. One patient presented with chronic kidney disease for which she was treated with hemodialysis. Electromyographic examination revealed evidence of denervation in the muscles of the lower limbs. Conduction velocities were slightly below the normal range. Rectal and/or sural nerve biopsy revealed the presence of amyloid deposit. Molecular analysis showed that all patients were heterozygotes for the TTR Met30 mutation. Eleven patients underwent orthotopic liver transplantation (OLTx) from 1993 to 2013. Eight of them showed remarkable improvement especially of their autonomic symptoms and muscle strength. They gained weight and their paresthesias also subsided. Of the operated patients, two died of post-operative complications, one of intracerebral hemorrhage and one of unrelated cause. Conclusion: FAP that occurs on the island of Crete is due to Met30 mutation. Haplotype analysis that is in progress may help to elucidate the origin of this mutation in relation to other populations. Our results regarding Orphanet Journal of Rare Diseases 2015, Volume 10 Suppl 1 http://www.ojrd.com/content/10/S1/I1 the liver transplantation corroborate those of other groups suggesting that this is the most effective treatment currently available for FAP.
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The phenotypical expression of an European inherited TTR amyloidosis in Brazil Márcia Waddington Cruz 1* , Débora Foguel 2 , Amanda Berensztejn 3 , Roberto Pedrosa 3 , Priscila Ferreira da Silva 2 1 Federal University of Rio de Janeiro, CEPARM. Neurology, 21941913, Rio de Janeiro, Brazil; 2 Federal University of Rio de Janeiro, CEPARM. Instituto de Bioquímica Médica, 21941913, Rio de Janeiro, Brazil; 3 Federal University of Rio de Janeiro, CEPARM. Cardiology, 21941913, Rio de Janeiro, Brazil Orphanet Journal of Rare Diseases 2015, 10(Suppl 1):O7 Background: Brazil is a country of Portuguese colonization with massive numbers of immigrants and Portuguese descendants (25 millions). At least half of all Brazilian Y chromosomes are from Portuguese origin. Nevertheless, this population suffered miscegenation with native Indians and African descendants. African descendants Brazilians have 48% of non-African genes, probably from Portuguese ascendance. In a previous work from our center a common haplotype was demonstrated in Portuguese and Brazilian patients from 22 families and the calculation of the most recent common ancestor in 13 families demonstrated that it has occurred at 26 past generations about 650 years ago hence before the time of Brazil's discovery (1500) [1] . The objective of this work is to characterize demographic and clinical aspects of Brazilian patients presenting with ATTR in light of the clear Portuguese origin of the cases in a background of miscegenation and heterogeneity of the population. Methods: Baseline clinical and demographics aspects of Brazilian patients included into THAOS (Transthyretin Amyloidosis Outcomes Survey) patient registry were extracted from 2007 to January 2015 in a total of 148 patients (68 women and 80 men). Results: Val30MetTTR mutation was found in 91.9% of the cases. Other mutations included Ile107Val, Val122Ile, Ala19Asp and Gly53Glu. The mean age at onset of disease was 37 years for men and 35 years for women. Mean time from onset of symptoms to diagnosis was 5.9 years (median 3.3 years). 93.9% informed a family history with more than 90% of Portuguese origin and 69% with aspects from Caucasian ethnicity. In 23% of the cases, the diagnosis in family members was based on clinical suspicion only. Amyloid deposit was found in 80% of the biopsies performed (34% salivary gland, 38% nerve and 3.7 cardiac). Misdiagnosis was noticed in 27.4% of the cases (26% of Val30Met mutations and 37.5% of non Val30 Met mutations cases) with CIDP being the most common. 25% of the patients took more than 1 year to have their correct diagnosis. From 117 symptomatic patients 79.5% presented with motor neuropathy (78% Val30 Met and 87.5% non-Val30Met); 85.5% presented with sensory neuropathy (85% Val30 Met and 87.5% non-Val30Met); 93% presented with autonomic neuropathy (93.6% Val30 Met and 87.5% non-Val30Met); 80.3% presented with gastrointestinal complaints. Unintentional weight loss was present in 50% of the cases. 80.6% of early onset cases presented with a motor neuropathy and 78.3% of late onset. Corresponding numbers for sensory neuropathy were 87% and 82.6%; and 94.6% and 87% for autonomic neuropathy. Cardiac disorders were noted in 35.9% of the cases (33.9% Val30 Met and 62.5% non-Val30Met 33.9%) (NYHA 1 or > in 3% of patients with early onset and 17.4% of late onset). ECG abnormalities were found in 56% of the cases (71% being conduction abnormalities). Left ventricular septum > 10 mm was seen in only 25% of the cases. Conclusion: The population was mostly characterized by early onset TTR Val30Met neuropathic phenotype presentation, with several cases also featuring some degree of cardiac disease, very similar to cases from endemic regions of Portugal even after several generations from the original immigration and a very important mixed racial population. Reference 1. Cruz MW: Regional differences and similarities of familial amyloidotic polyneuropathy (FAP) presentation in Brazil. Amyloid 2012, 19(Suppl 1):65-67. (10). In these ATTRwt amyloidosis patients, the mean change from baseline in 6MWD (+/-SEM) at 6 (N=125), 12 (N=88) and 18 (N=55) months was -30m (7), -59m (13) and -89m (16) respectively. In our previously reported data in FAC patients (N=137, median age 72 yrs, 40% NYHA class II, 43% NYHA class III), median survival (95% CI) was 34.1 months (28.6, 38.5). For a subset of FAC patients in whom 6MWD data was available (N=39, median age 76 yrs, 59% NYHA class II, 38% NYHA class III), mean baseline 6MWD (+/-SEM) was 281m (20), and mean change from baseline in 6MWD (+/-SEM) was -36m (23), -106m (24) and -140m (39) at 6 (N=32), 12 (N=27) and 18 (N=16) Background: Transthyretin (TTR) Val30Met-associated familial amyloid polyneuropathy (FAP ATTR Val30Met) is the most common form of FAP and has become prevalent in areas other than conventional endemic foci. The clinicopathological features of FAP ATTR Val30Met are known to vary between endemic foci and non-endemic areas in Japan. Characteristic features of early-onset cases from Japanese endemic foci include the presence of sensory dissociation and marked autonomic dysfunction associated with a predominant loss of small-diameter myelinated and unmyelinated nerve fibers. These characteristics are uncommon in lateonset cases from non-endemic areas.
Methods: We examined sural nerve biopsy specimens from 42 patients with FAP ATTR Val30Met using electron microscopy, particularly focusing on the morphology of nerve microvascular endothelial cells. This study included 5 early-onset cases from endemic foci (3 men and 2 women) and 37 late-onset cases from non-endemic areas (33 men and 4 women).
Results: Greater amyloid deposition was observed in early-onset cases than in late-onset cases, whereas reduced nerve fiber density was more conspicuous in late-onset cases than in early-onset cases. Retraction of the processes of Schwann cells associated with amyloid fibrils was observed, particularly in early-onset cases. In addition, basement and cytoplasmic membranes of Schwann cells associated with amyloid fibrils were indistinct, indicating that direct invasion of amyloid to Schwann cells had resulted in predominantly small-fiber axonal loss characteristic of early-onset cases. In late-onset cases, nerve microvascular endothelial cell morphology was frequently found to be abnormal with loss of tight junctions and fenestrations. Conclusion: These findings suggest that, in addition to direct invasion of amyloid to Schwann cells, the disruption of the blood-nerve barriers contributes to the pathogenesis of neuropathy in FAP.
The disease can be difficult to recognize due to extreme phenotypic heterogeneity and nonspecific clinical symptoms even within the same mutation.
In TTR-FAP related to Val30Met mutation, different neuropathy phenotypes have been reported mainly in patients from non endemic areas as well in late onset cases. Case report: We described 3 TTR-FAP Val30Met early onset cases from endemic areas with a different neuropathy phenotype that can be easily misdiagnosed as a different entity. One case presented as a bilateral carpal tunnel syndrome without neuropathy; another with a demyelinating neuropathy with predominant upper limb involvement and other with a demyelinating neuropathy with conduction blocks mimicking a CIDP. Conclusion: For the first time, we were able to prove that alterations of the evaluated quantitative markers were highly specific: Asymptomatic carrier-status and symptomatic disease were both closely associated with a strong increase of proton-spin-density, while a significant increase of the T2-relaxation-time was found only in symptomatic TTR-FAP, but not in asymptomatic carriers. These findings suggest that proton-spin-density is more sensitive for the detection of early or even subclinical nervelesions, while T2app may serve to specifically differentiate increasing disease severity in already symptomatic TTR-FAP. Background: 99mTechnetium labelled 3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD) scintigraphy has been re-purposed in recent years as a sensitive non-invasive method for imaging transthyretin (ATTR) cardiac amyloid. We have routinely performed DPD scans since June 2010 at the National Amyloidosis Centre in London, and review here our findings in a large cohort of mostly British patients. Methods: Following administration of 99mTc-DPD, patients underwent whole body planar imaging three hours after injection followed by a cardiac SPECT-CT (single photon emission computed tomography with a low-dose, non-contrast CT scan). As of December 2014 we had performed 1454 DPD scans on a total of 1191 patients, which formed the basis of our cohort for analysis. Results: The most frequent amyloid types seen were light chain (AL) (n=277), wild-type ATTR (n=372) and hereditary ATTR (n=237). Of those AL patients with a positive scan (n=75), 24% had grade two or higher uptake compared to wild-type ATTR in which 95% of positive scans were grade two or three. A total of 22 different TTR variants were identified, most commonly Val122Ile (43%), Thr60Ala (25%) and Val30Met (16%); cardiac uptake at clinical presentation of patients with TTR Val122Ile and Thr60Ala were grade two or higher in 99% and 98% of cases respectively. Conversely, of the 16 TTR Val30Met patients with positive scans, four were grade one and the rest grade two. Interestingly, nine patients with the TTR Ser77Tyr mutation were studied, and despite a median left ventricular wall thickness of 15.5mm (range 13.5 -20.0 mm), cardiac DPD tracer uptake was less than patients with other mutations who had an apparently similar amount of amyloid. Cardiac amyloidosis was ultimately excluded in 256 patients, in none of whom was there any cardiac uptake of DPD. Two patients with cardiac DPD uptake were found to have both AL and ATTR amyloid fibrils on cardiac biopsy. Positive scans were obtained in three patients in whom cardiac biopsies were negative for amyloid. DPD scintigraphy was also performed on four patients who had received domino liver transplants from donors with familial amyloid polyneuropathy (one with Val30Met mutation). Cardiac uptake was seen in one patient (Phe33Val) who, eight years post transplantation, has now progressed to develop cardiac, peripheral and autonomic disease. Extra-cardiac uptake of DPD was also noted, including soft tissue/skeletal muscle uptake in ATTR and AL patients, in some cases virtually obscuring cardiac tracer uptake. Lymph node and uptake in some cases of localized AL amyloidosis were also seen. Conclusion: DPD scintigraphy has proved to be a remarkably sensitive tool for the diagnosis and exclusion of clinically significant ATTR cardiac amyloidosis. Extra-cardiac uptake of DPD in amyloid deposits is an interesting phenomenon which warrants further investigation.
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Multi-modality imaging in cardiac ATTR amyloidosis: agreement between echocardiography, MRI and DPD- Conclusions: As of June 8th 2015, 25 patients have been enrolled in the OLE. Interim 6-month data on safety, PD and clinical outcomes will be presented.
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The ISIS-TTRRx-CS2 phase 3 study in patients with familial amyloid polyneuropathy: Baseline results of the first 100 patients for the NIS, NIS+7 and mNIS+7 using different methods of scoring: identification of consistencies and key differences Background: Familial amyloid polyneuropathy (FAP) is a devastating disease with continuous progression over time leading to complete disability, bedridden status, and ultimately death within 10 to 15 years from symptom onset. In order to document disease progression, it is necessary to have valid instruments which allow assessment of the severity of the sensory, motor and autonomic neuropathy components of the disease. Over the last decades, multiple related instruments have been used and modifications developed to measure disease progression in FAP patients in clinical trial settings. These include the Neuropathy Impairment Score (NIS), originally called Neuropathy Disability Score, the Neuropathy Impairment Score for the Lower Limbs (NIS-LL), the Neuropathy Impairment Score +7 (NIS+7) and the modified NIS +7 (mNIS +7). The NIS scores were first used to quantitate neuropathic impairment in a series of therapeutic trials in chronic inflammatory demyelinating polyradiculoneuropathy and were also used as primary endpoints in clinical trials for FAP in the completed diflunisal (NIS+7) and tafamidis (NIS-LL) Phase 3 trials. Building on experience from these trials, modifications to the NIS+7 were developed (Suanprasert et al, 2014, J Neurol Sci) and are currently being applied in the ongoing ISIS-TTRRx-CS2 (mNIS+7 Isis) and patisiran (mNIS+7 ALN) Phase 3 trials. Even though the mNIS+7 Isis and mNIS+7 ALN scores are very similar, they are not identical. The details in the assessment and scoring for the various versions of the NIS based scores are described and their scoring methods applied to baseline data collected on the first 100 patients in the ISIS-TTRRx-CS2 trial to better understand and illustrate the key differences. Methods: The demographics and neuropathic status of the first 100 patients enrolled in the ISIS-TTRRx-CS2 trial were analysed. At baseline, all assessments needed to calculate NIS, NIS-LL, NIS+7 and mNIS+7 Isis were obtained in duplicate. All assessments required to calculate the mNIS+7 ALN were also obtained except for postural blood pressure, which accounts for < 1% of the mNIS+7 ALN score. Data are presented using descriptive statistics. Results: The most common mutation was Val30Met followed by Thr60Ala. The mean age was 62 yrs (range 27-81) and 76% were male. The differences in the NIS based scales and impact of the changes in relative weights of the sub-scores were investigated. The results will be presented for each score and scoring method and will include the baseline data for NIS (median 41; range 3 -106), NIS+7 (median 57; range 10 -120) and mNIS+7 Isis (median 74; range 10 -163). Conclusion: As interest in developing improved therapeutics for FAP continues to grow and as more physicians are recognizing and following FAP patients in clinical practice, it is important that the differences between the various instruments used to measure disease progression are acknowledged, compared and understood.
Background: The transthyretin (TTR) stabilizer diflunisal has been shown to reduce the rate of progression of neurological manifestations in patients with hereditary ATTR amyloidosis. However, data on the effect of diflunisal on cardiac structure and function in amyloidotic hearts are lacking. We report the echocardiographic profiles and cardiac biomarkers of patients with either mutant (M) or wild-type (WT) TTR-related cardiac amyloidosis (ATTR-CA) who received treatment with diflunisal compared to matched untreated patients. Methods: We included in the analysis patients with clearly defined ATTR-CA, who received diflunisal for at least 24 months. For comparison, we included a group of patients with similar age, left ventricular (LV) wall thickness and renal function who were not treated with diflunisal. Patients with coexistent rhythm abnormalities (e.g. atrial fibrillation) or pacemaker implantation were excluded. All subjects underwent a standardized comprehensive protocol of evaluations and follow-up. NT-proBNP increased in both the untreated group (from 6.2±0.7 to 6.9±0.6 ng/L, p<0.001) and (less) in the treated one (from 5.9±0.9 to 6.2±0.7 ng/L, p=0.02; generalized estimating equation p<0.01), in the absence of a significant decrease of eGFR over time, both between groups (generalized estimating equation p=0.29) and within each group (from 69±17 to 65±20 ml/min in the treated group, p=0.19; from 63±20 to 55±22 ml/min in the untreated group, p=0.07).
Conclusion: The use of sensitive markers of change in cardiac function, such as GLS and NT-proBNP, suggests that diflunisal may slow or halt disease progression in mutant and wild-type ATTR-CA. These findings encourage further systematic study of diflunisal in ATTR-CA. Background: TTR stabilizers have proved effective in slowing neurological progression in FAP. However, wider experience outside trials is required to further establish their safety profile and clinical benefit in the general FAP population.
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Objective: We evaluated the safety and efficacy of diflunisal (250 mg BID) in late-onset FAP patients with moderate to severe neuropathy and cardiomyopathy treated for at least 24 months. Methods: Evaluations included Kumamoto score, polyneuropathy disability score (PND), mBMI, echocardiography and cardiac biomarkers. Adverse events were monitored every three months. Response was evaluated every 12 months.
Results: 24 patients (20 males) affected by FAP associated with 7 different mutations were treated for a median of 24 months (range 12-60). Median age at baseline was 69 years (range 57-82), disease duration 43 months (range 17-90), PND score IIIA (range I-IV), Kumamoto score 25 , BMI 890 (range 604-1458). 21 patients presented with heart involvement. Median NT-proBNP was 728 pg/ml (range 141-5965), cTnI 0.04 ng/ml (range 0.029-0.65), mLVW 14.2 mm (range 12.5-17.5). PND increased by 1 point from baseline in 8/18 patients. mBMI remained stable during treatment. Mean change in Kumamoto score was 2.9/year (95% CI -0.3 to 4.8). Cardiac progression occurred only in 2/21 patients. One patient discontinued due to renal failure and three presented with a mild increase in serum creatinine. One patient discontinued after 3 years of treatment due to asymptomatic TnI increase that improved following discontinuation. No GI events were recorded. ,1982 , , Canavarro,1999 , , 2007 were applied to these patients. BSI is an inventory that evaluates 9 psychopathological dimensions (somatization, obsession-compulsion, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation, psychoticism) and includes a global symptom index (GSI). Statistical analysis was applied (descriptive analysis, Mann-Whitney and Wilcoxon, Spearman tests).
Results: Considering Global Symptom Index (GSI), 32.7 % of total subjects were above media for general population. When sub groups were evaluated, 25.6% of symptomatic carriers,26.3 % of subjects without established diagnosis and 39.1% of patients were above media. All dimensions of BSI were significantly higher in the group of patients when compared with that of the carriers, with the exception of obsession-compulsion, phobic anxiety and interpersonal sensitivity. The global symptom index was significantly higher in patients (p=0.001). When we considered differences between gender, women who were asymptomatic carriers had statistically significant more phobic anxiety (p=0.01) and almost significant interpersonal sensitivity, anxiety and depression.
In the group of patients, almost all dimensions scored significantly higher for women, with the exception of somatization (p=0.065).
In the group of patients, all dimensions and GSI (rho=0.33, p=0.002) had positive correlations with years of disease, except for interpersonal sensitivity.
In patients, only the hostility dimension had positive correlation (rho=-0.234, p=0.031).
Conclusions: A high number of FAP patients have psychopathological symptoms and also asymptomatic carriers, have scores above those for general population, in a significant number. The group of patients are at higher risk for most of the psychopathological dimensions. Sick women are more vulnerable to psychological distress, and as time goes by, patients may have more psychic problems. Assuming that these values represent the patients' preferences and the utility associated with their health state, the results presented in this study may be used in future health technologies cost-utility studies.
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Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin Background: Amyloidoses are a progressive, systemic disease caused by the accumulation in tissues of misfolded proteins that induces multiorgan dysfunction. The most common hereditary form is transthyretin amyloidosis (ATTR), caused by the accumulation of transthyretin protein (TTR). There are no approved pharmacologic therapies for ATTR in the United States, and liver transplantation is the only disease-modifying treatment. TTR, a redundant thyroxin transport protein, comprises four single-chain monomers assembled into a tetrameric complex in its native state. During the amyloidogenic process, the tetramer dissociates into monomeric subunits that then undergo conformational change, making them more prone to aggregation and fibril formation. Comparison of the crystal structure of tetrameric TTR and the monomeric TTR identified a region that is inaccessible in the tetramer but exposed upon monomer dissociation. By targeting this site with a monoclonal antibody (mAb), it might be possible to prevent TTR monomers from assembling into fibrils without influencing the function of the native tetramer. The objective of this study was to produce mAbs targeting this exposed epitope of monomeric TTR and to (a) demonstrate conformational specificity toward misfolded versus native forms of TTR and (b) determine whether they are able to recognize TTR deposits in diseased tissue. Methods: Mice were immunized with a multiple antigenic peptide comprising the target sequence identified in the structural analysis of TTR. Clones were screened for reactivity against misfolded TTR fibrils and counter-screened against native tetrameric TTR. Selected mAbs were characterized by sandwich ELISA, SPR, and Western blot. Immunohistochemistry was performed in combination with Congo red and thioflavin-T staining to demonstrate specificity to TTR-amyloid in ATTR patient-derived tissue sections. Results: Four mAbs were identified that bind to the target epitope on monomeric and nonnative conformations of TTR. These mAbs bound nonnative forms of TTR (KD values 7.7-18.6 nM) but, importantly, did not recognize native tetrameric TTR. These mAbs also recognized TTR deposits in a variety of ATTR heart tissues. They did not recognize control heart tissue (normal or AL amyloidosis) or the native tetrameric TTR present in human liver tissue.
Conclusions: Conformation-specific mAbs immunoreact with an amyloidogenic epitope of TTR but not with native tetrameric TTR. These mAbs specifically recognize TTR deposits in ATTR heart tissue, not in control tissue (normal and AL amyloidosis). These novel mAbs may be useful in preventing deposition and/or enhancing clearance of TTR amyloid in ATTR patients. (24):2658-2667) where quality of life, neuropathy impairment scores and nutritional status showed significant, though modest, better results in patients randomised to receive diflunisal instead of placebo. Methods: We aimed at describing the first off-label (compassive) use of diflunisal in a small cohort of 10 patients affected by variable degrees of TTR-FAP in our centre. A protocol for off-label use Diflunisal was introduced and accepted early in 2014 by the amyloidosis and monoclonal gammopathies' unit (UDAM) at Hospital Clínic de Barcelona. Inclusion criteriae consisted of any symptomatic hereditary TTRamyloidosis patient with progression of FAP either (i) unfit or unwilling to receive either liver transplantation (LT)/Vyndaqel® as per on-label indication or to enter an ongoing clinical trial (e.g. RNA silencing), (ii) already under on-label treatments (Vyndaqel®, liver transplantation (LT)) or (iii) any Domino-LT (DLT) recipient with de novo signs/symptoms of polyneuropathy with biopsy proven culprit ATTR deposits. Exclusion criteriae consisted of a known previous adverse reaction to Diflunisal, estimated GFR <60mL/min/1.73m2, concommittant lithium therapy, reninangiotensin-aldosterone system antagonists, being already under investigational drug or tafamidis, Karnofsky score <40 and unwillingness to comply to follow-up. Basal demographic and clinical characteristics were collected. Follow-up was performed every 2 months with particular attention to disease progression "red flag" signs (polyneuropathy, dysautonomy, ECG) and incidence of adverse events.
P2
Results: A total of 10 patients were included. After a median follow-up of 8 months, diflunisal showed overall improvement of neuropathic pain and quality of life as well as stabilisation of disease stage. Mean initial eGFR was 83 and did not change significantly. Three cases presented transient acute renal failure that recovered once diflunisal dose was lowered, without a detrimental effect on TTR-FAP. Conclusion: This is the first Spanish report of diflunisal off-label use in the setting of hereditary TTR-FAP. Diflunisal seems a relatively safe and effective option for patients with TTR-FAP in progression and who are not candidates for other therapies. Particular attention must be paid to renal function as dose adaptation may be warranted.
P3
The Results: Our data show that inhibition of TTR expression by the liver prevent and reverse TTR deposition in PNS and GI tract. In addition, this treatment resulted in ECM remodeling with decreased levels of matrix metalloproteinase-2 (MMP-2) expression and MMP-9 activity in dorsal root ganglia. Importantly, MMP-2 protein levels were found down regulated in plasma samples from older mice treated with RNAi while animals treated with Tafamidis, Anakinra or Doxycycline/TUDCA showed no difference, suggesting that ECM remodeling with decreased MMP-2 might be a specific effect of RNAi. Conclusion: Collectively, our data show that silencing TTR liver synthesis in vivo can modulate TTR-induced pathology in the PNS.
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Background: Tafamidis is a transthyretin (TTR) stabilizer able to prevent mutated TTR tetramer dissociation into amyloidogenic monomers. There have been a few encouraging studies on safety and long-term efficacy of Tafamidis in early-onset Val30Met TTR-familial amyloid polyneuropathy (TTR-FAP) patients. However, less is known about its efficacy in later stages of the disease and in non-Val30Met mutations. Methods: Multi-center observational study on symptomatic TTR-FAP patients prescribed to receive tafamidis. We followed up patients according to a standardized protocol including general medical, cardiological and neurological assessments at baseline and every 6 months up to 3 years. Results: 61 (42 males) patients were recruited. Only 28% of enrolled subjects had the common Val30Met mutation, mean age of onset was remarkably late (59 years) and 18% was in an advanced disease stage at study entry. Tafamidis proved safe and well-tolerated. One third of patients did not show significant progression along 36 months, independently from mutation type and disease stage. Neurological function worsened particularly in the first 6 months but slowed significantly thereafter. Fifteen percent of patients showed cardiac disease progression and 30% new onset of cardiomyopathy. A higher mBMI at baseline was associated with better preservation on neurological function. Conclusions: Neuropathy and cardiomyopathy progressed in a significant proportion of patients despite treatment. However, the worsening of neurological function slowed after the first 6 months and also subjects with more advanced neuropathy, as well as patients with non-Val30Met mutation, benefited from Tafamidis treatment. Body weight preservation is an important favorable prognostic factor. Background: Transthyretin (TTR) amyloidosis is a progressive and fatal systemic disorder caused by misfolded TTR monomers that cumulatively deposit in the heart, peripheral nerves and other organ systems. TTR Amyloidosis-associated cardiomyopathy (ATTR-CM), caused by TTR amyloid infiltration of the myocardium and conduction system, results in a restrictive cardiomyopathy associated with atrial arrhythmias, progressive heart failure with preserved ejection fraction in early phases, and leads to reduced life expectancy. ISIS-TTRRx is a first-in-class, 2ndgeneration antisense oligonucleotide designed to produce substantial reductions in the levels of both mutant and wild type TTR produced from the liver. Methods: We plan to conduct a Phase 3 randomized, double-blind, placebo-controlled, global study designed to evaluate the efficacy and safety of ISIS-TTRRx in patients with ATTR-CM. The study will evaluate the differences observed between patients treated with placebo and with ISIS-TTRRx over 24 months evaluating several key endpoints. Serum biomarkers including circulating TTR levels, NT-pro-BNP and troponin, imaging endpoints including global longitudinal strain by echocardiography, clinical outcomes including mortality, transplants, cardiovascular hospitalization and arrhythmic events, and clinical status including New York Heart Association (NYHA) class, and the patientreported instrument Kansas City Cardiomyopathy Questionnaire (KCCQ) will be evaluated. The trial is designed to enroll approximately 400 ATTR-CM patients with documented senile systemic amyloidosis (SSA) or documented familial amyloid cardiomyopathy (FAC), including theVal122Ile mutation and other TTR mutations, in addition to biopsyproven amyloid deposits. Patients will be randomized 2:1, ISIS-TTRRx: placebo, with ISIS-TTRRx administered subcutaneously at 300 mg every other day for five days, then weekly for 24 months. The study will have 85% power to detect a difference between treatment groups in the final primary endpoint, with a significance level of p < 0.05. All patients completing the Phase 3 study will be eligible to enroll in a Phase 3 openlabel extension study or otherwise receive access to ISIS-TTRRx. An academic Steering Committee will oversee trial conduct, an independent Clinical Event Committee will adjudicate study outcome endpoints, and an independent Data Safety Monitoring Committee will periodically review and evaluate accumulated study data for participant safety and, when appropriate, efficacy, and make recommendations to the sponsor and Steering Committee concerning the continuation, modification, or termination of the trial.
Results and conclusions:
Results of the trial are anticipated in 2019. The trial will establish the role of therapy with ISIS-TTRRx. in this patient population for whom effective treatments to alter the progression of the disease are needed. Background: Transthyretin amyloidosis is a protein aggregation disorder caused by deposition of transthyretin, a tetrameric plasma protein in charge of the transport of thyroxin and retinol in plasma and cerebrospinal fluid. Kinetic stabilization of the TTR tetramer has proved to be a valid therapeutic strategy to prevent the release of unstable TTR monomers and their aggregation into oligomers and amyloid fibrils. SOM0226 is tolcapone, a repositioned compound with a newly identified activity as a potent TTR stabilizer and TTR fibril disruptor.
Methods: A proof of concept Phase IIa clinical trial has been conducted in diagnosed Familial Amyloid Polyneuropathy (FAP) patients, asymptomatic carriers and healthy volunteers with the objective to determine whether treatment with SOM0226 stabilizes plasmatic TTR. The trial has been conducted at the Hospital Universitari Vall d'Hebron (Barcelona) and has involved 6 healthy individuals and 15 asymptomatic carriers with mutations in the TTR gene and FAP patients at different stages of disease progression. It was an interventional open label study organized in two phases separated by a washout period of 6 weeks. During the first phase, patients were administered a single dose of SOM0226 (200mg) and blood was collected at different times for determination of drug levels and TTR stabilization activity, which was the primary efficacy endpoint of the study. The second phase was similar but involved multiple doses of 100mg of SOM0226: one every 4 hours up to a total of 3 doses. TTR stabilization was measured in plasma samples using an immunoturbidity method after urea denaturation and crosslinking with glutaraldehyde. Safety endpoints were also determined at baseline and at the end of each phase. Results: Treatment with a single oral dose of 200mg or three doses of 100mg SOM0226 induce a clear and robust stabilization of plasmatic TTR in all patients studied, allowing the protection of 100% of TTR present in the plasma samples. This activity is maximal after 2 hours of dosing and clearly correlates with drug levels in plasma. The studied administration regime has demonstrated to be safe, with no adverse events related to the investigational product observed. Moreover, significant clinical or analytical hepatotoxicity has not appeared in any patient. Conclusion: SOM0226 is capable of stabilizing all TTR present in plasma samples in all patients studied, supporting further development of SOM0226 for the treatment of TTR amyloidosis. As a repositioned drug, SOM0226 (tolcapone) can bypass much of the early cost and time needed to bring a drug to market and bears the potential to become the most potent TTR stabilizer in the market to prevent the progression of the different forms of TTR amyloidosis. Background: Different compounds have been studied for the treatment and/or symptoms amelioration of Familial Amyloidotic Polyneuropathy (FAP). We previously showed that Tauroursodeoxycholic acid (TUDCA), a biliary acid with anti-oxidant properties known to reduce non-fibrillar TTR aggregates is also capable of diminishing ER stress by its action on Bip in young transgenic Val30Met mice. This compound has already proved to be neuroprotective in several studies using genetic animal models of Huntington's and Parkinson's disease although the mechanisms underlying its neuroprotection action are still unknown. Other cellular mechanisms are being explored for possible actions of TUDCA, with special highlight to autophagy, a cellular mechanism that involves the delivery of large protein aggregates, defective organelles and other cellular debris to lysosomes for degradation that has lately been linked to several degenerative diseases where it appears to be impaired. The objective of our work is to investigate whether improvements previously observed in TUDCA-treated Val30Met mice involves autophagy. Methods: For this study, nine months old mice bearing the human TTR Val30Met mutation, in a TTR null background-hTTR Met30 were used. Animals were treated with TUDCA (500 mg/kg/day) in the drinking water, for a 3 month period after which the animals were sacrificed and organs from gastrointestinal tract were collected. An age-matched control group of animals was maintained in the same conditions, drinking regular tap water. Immunohistochemistry analyses were performed in order to evaluate the expression levels of an autophagic marker, p62, a protein naturally degraded in the final steps of the autophagic flux and that typically accumulates when autophagy is impaired. Results: Our preliminary results point to a significant reduction in p62 accumulation in colon samples of TUDCA treated mice. Conclusion: TUDCA is a promising compound that has already been proved to significantly reduce TTR toxic aggregates in vivo which points to its capability of modulating TTR aggregation by cellular responses, such as by oxidative stress, ER stress and apoptosis. Our results indicate that this modulation involves the autophagic machinery where it seems to enhance/restablish the autophagic flux that in turn may be directly involved in the pathological cascade in FAP, thus TUDCA contributes to the clearance of Val30Met TTR aggregates. Background: Safety and efficacy of once-daily 20 mg tafamidis, a transthyretin (TTR) stabilizer, was evaluated in an 18-month, multicentre, randomized, double-blind, placebo-controlled study in 128 patients with early symptomatic V30M TTR familial amyloid polyneuropathy (TTR-FAP).
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In the intent-to-treat population, a responder analysis for Neuropathy Impairment Score-Lower Limb (NIS-LL) (co-primary with Norfolk Quality of Life-Diabetic Neuropathy) favoured tafamidis (P=0.07). A pre-specified, key secondary analysis of change from baseline to Month 18 in NIS-LL continuous scores was significant (P=0.04). Placebo-corrected point estimates for 5 pre-specified and validated measures of disease progression also favoured tafamidis and were directionally consistent. Additional post-hoc analyses supporting tafamidis for delaying progression of TTR-FAP are reported here. Background: Tafamidis is a transthyretin (TTR) stabilizer approved to delay neurological progression associated with stage 1 TTR familial amyloid polyneuropathy (FAP). A placebo-controlled, randomized 18-month registration trial allowed for continued evaluation of patients receiving tafamidis (20 mg oral once-daily) through an ongoing open label extension study. The effectiveness of tafamidis for delaying long-term neurological progression relative to baseline levels of neuropathy impairment at the start of treatment has not been reported previously.
Methods: This analysis describes the trajectory of the disease progression over 5.5 years or more for 71 patients with the V30M mutation and stage 1 TTR-FAP who received tafamidis either at the start of the registration trial or after the switch from placebo following 18 months of study participation. All V30M patients treated with tafamidis in the original trial or its extension and for whom follow-up data were available were included. The impact of tafamidis on neurological progression over time was evaluated using the Neuropathy Impairment Scale for lower limbs (NIS-LL). Baseline NIS-LL at active treatment start was defined as the last measurement before the first active dose of tafamidis. Results: Patients (30 male, 41 female) were primarily Caucasian (91.5%) with a mean (standard deviation [SD]) age of disease onset of 35.7 (11.31) years. Very low baseline disease severity, defined as NIS-LL ≤10 at treatment start (baseline mean NIS-LL [SD] = 4.1 [3.1]), was associated with a minimal level of disease progression over time. Mean change in NIS-LL from baseline (SD) over 5.5 years of treatment was: 0.6 (3.2) at 1 year, 1.3 (3.7) at 2 years, 2.3 (6.0) at 3 years, 1.7 (4.8) at 4 years and 5.3 (10.1) at 5.5 years. Additional categorization of patients according to baseline NIS-LL of 0-5 and 5-10 revealed a similar pattern of reduced disease trajectory. For 3 patients, there was evidence after 3-5 years of treatment of an increase in the NIS-LL score to 30 or more. Conclusion: Early intervention with tafamidis provides long-term benefit in delaying neurological progression associated with TTR-FAP. These data underscore the need to intervene as early as possible with symptomatic TTR-FAP patients. Note: First presented at the Peripheral Nerve Society Congress, Montreal, Canada, June 2015. Background: We previously showed the properties of interleukin-1β antagonist Anakinra on unmyelinated nerve fibers protection in a transgenic mouse model for human V30M transthyretin. In these studies, Anakinra decreased, among other markers, nerve levels of IL-1β, NF-B and activated-caspase 3, associated with a decrease in TTR-non fibrillar deposition.
In the present work, we compared the efficacy of other compounds under human therapeutical trials for Familial Amyloidotic Polyneuropathy (FAP) in the same animal model, having 5 months of age. Methods: V30M transgenic mice were treated daily with subcutaneous injections of Anakinra at 25 mg/kg over 6 weeks. Age-matched controls were injected with phosphate buffer saline (PBS). TTR siRNA, at a concentration of 1 mg/kg was injected in the tail vein for 4 weeks. One intravenous injection was performed per week and animals were euthanized 48 h after the last injection. Untreated age-matched controls received vehicle intravenously. Anakinra plus TTR siRNA combination therapy was performed using the same therapeutical design. In addition, other V30M mice group was treated with Tafamidis meglumine with 3 subcutaneous injections weekly, over 6 weeks. Controls received meglumine alone. Finally, combination strategy with Doxycycline/TUDCA was also achieved in V30M mice. Animals were treated with 8 mg/kg Doxycycline daily in the drinking water and received intraperitoneal injections of 500 mg/kg TUDCA twice a week for 4 weeks. Controls were injected with intraperitoneal PBS. After mice sacrifice, nerves were collected into a 0.1 M sodium cacodylate solution containing 1.25% glutaraldehyde and 4% paraformaldehyde for posterior fiber counting. Nerves from animals treated with Anakinra, TTR siRNA or both agents combined were also analyzed by immunohistochemistry for inflammatory and apoptotic markers, namely NF-B transcription factor, IL-1β and FAS death receptor.
Results: In contrast with Anakinra treatment alone, no differences in both myelinated and unmyelinated fiber density as compared with vehicle were found for the other tested compounds. However, combined Anakinra and siRNA administration resulted in increased density of unmyelinated fibers as compared to controls. Efficiency of Anakinra as a neuroprotective molecule was corroborated in sciatic nerve analyses of NF-B, FAS death receptor and IL-1β in animals treated with a combination of Anakinra and siRNA, since these markers were found downregulated in animals receiving this combined therapy. Mice treatment with single protocols of siRNA, Tafamidis or Doxycycline/TUDCA, did not change levels of the selected biomarkers.
Conclusion: Anakinra should be considered for its potential in single and/or combination protocols for FAP studies. mutant transthyretin (TTR) Val30Met gene. We present a case of a pair of MZ twins associated with a substitution of tyrosine to cysteine at position 114 in the TTR gene in a Russian kindered. Until now FAP due to mutant TTR Cys 114 has only been described in one Japanese and in one Dutch family. Though in none of them MZ twins were present. Materials: Complete laboratory and instrumental investigation of both of the Russian MZ twins was performed. Detailed life history was evaluated in each of the brothers and compared with other known cases of FAP in MZ twins. Results: One of the twins had a prominent clinical picture of FAP and visceral amyloidosis, starting around the age of 45 years. In the mean time the other brother was still clinically healthy at the age of 50. DNA confirmed identical mutation of TTR gene in both brothers. Amyloid depositions were found to be similar in the intestines, but not in other locations. Both patients lived in same district and had similar educational background. Though the patient with a prominent clinical picture of FAP experienced vaccination agravated by side effects as well as appendicitis agravated by severe peritonitis in his twenties. Conclusion: Charactristic feature of FAP in known pairs of MZ twins is the discordance in the disease course with a prominent manifestation in one of the twins, and delayed disease onset and/or only slight presentation in the other. Genetical and non-genetical factors, or their combination, were supposed to be contributing. Non-genetical mechanisms of the phenotypic variability of FAP could consist of influences on the mutant gene expression during twinning process or along the life. In Russian pair of MZ twins different life-course events could determine clinical presentation of the disease. The prevalence of transthyretin (TTR) amyloidosis in Europe is supposed to be less than one per 100,000 individuals. Slovenia is a rather small country with approximately two million inhabitants and we know of two families with 4 patients with this disease. The first patient (family A) was diagnosed in 2008 when also one of the asymptomatic family members who agreed to molecular genetic testing was found to be a carrier. Other family members up to now disagreed with clinical, laboratory and molecular genetic testing. Patients from family B were diagnosed in 2014. Their siblings were found not to be carriers. The index case from family A was diagnosed at the age of 54. The TTR gene mutation was characterised as Val122Ala. First symptoms were due to dysautonomia and appeared 4 years earlier in the form of abdominal colic associated with vomiting and orthostatic hypotension. He also had symptoms and signs of length-dependent axonal polyneuropathy and hypertrophic restrictive cardiomyopathy. He died the day after liver transplantation. The disease of the family's B index case started approximately one and a half year before the diagnosis with pain in his feet, orthostatic hypotension, sexual impotence, diarrhoea alternating with constipation, and weight loss. Later on he also noticed weakness in his lower limbs but is still able to walk unaided. The Val30Ala mutation was found. Except to polyneuropathy no other organs are affected. He is treated with tafamidis. His sister is asymptomatic but is having electrophysiological signs of polyneuropathy and cardiac vagal denervation. She recently also started taking tafamidis. With increasing awareness of the transthyretin amyloidosis, especially amongst neurologists and cardiologists in our country, we expect to find some more patients in the near future, particularly among members of the affected families. Two other unrelated patients are currently undergoing testing, one of them with transthyretin amyloid tissue deposits. Hypothesis: There are conflicting data regarding survival in Val122Ile versus SSA cardiac amyloidosis, suggesting either better survival in SSA or similar survival between the groups. Since survival is often calculated from time of diagnosis, a delayed diagnosis in Val122Ile from symptom onset would bias survival toward SSA. We therefore sought to determine whether patients with symptomatic SSA and Val122Ile seen at our Program showed different patterns of referral, and whether one group had a longer time to diagnosis than the other.
Methods: Records of all 30 Val122Ile patients with cardiac involvement seen over an 8 year period were compared to records of 34 randomly selected patients with cardiac SSA. We estimated onset of cardiac symptoms likely due to amyloidosis from detailed history review and determined definitive diagnosis based on biopsy or (for Val122Ile) either biopsy or typical echocardiogram with positive genetic testing. Referral patterns were also determined, specifically whether patients were from within our home state or referred from out-of-state. Death was determined by national database of deaths, medical records or on-line obituary search if patient had been lost to follow-up.
Results: Mean age at diagnosis did not differ between groups: Val122Ile =71.4 yr, SSA =73.9 yr. There was a wide range of symptom duration between symptom onset and diagnosis, ranging from weeks to 9 years in both groups, with a slightly longer duration of symptoms in the SSA group than in Val122Ile (32.4 v 21.6 months p=ns). Actuarial survival from diagnosis did not differ between groups, being 33 months in Val122Ile and 36 months in SSA, but there was a a strong trend to better survival from symptom onset in SSA (66 months in SSA v 51 months in Val122Ile). Referral pattern differed significantly between the 2 groups, with 63% of Val122Ile patients referred from in-state compared to only 34% of SSA (p<0.05).
Conclusion:
The higher rate of out-of-state referrals for SSA may suggest either an increased awareness of the disease locally, or possibly a socioeconomic bias in favor of SSA patients. The trend toward earlier diagnosis from symptom onset in Val122Ile patients may affect analysis of survival comparison with SSA if date of diagnosis is used in calculating survival, but the overall median survival in both groups, whether from diagnosis or symptom onset remains poor, and underscores the pressing need for disease-modifying drug trials in both groups.
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Preliminary assessment of neuropathy progression in patients with hereditary ATTR amyloidosis after orthotopic liver transplantation (OLT) David Adams 1* , Juan Buades 2 , Ole Suhr 3 , Laura Obici 4 , Teresa Coelho 5 liver. In order to better understand the natural history of patients receiving FAP-OLT, we performed a retrospective assessment of time to polyneuropathy disability (PND) score progression. Methods: We characterized neuropathy severity with the (PND) score. Descriptive statistics including proportions of FAP patients who progress by at least one PND stage after OLT and median time to PND stage progression were assessed in available FAP-OLT patients in Sweden, Portugal, Spain, Italy and France from 1991-2015. The Italian cohort only included patients that had progressed, while patients from other countries included all-comers (progressors and non-progressors).
Results: A total of 362 FAP-OLT patients were preliminarily assessed from: Portugal, 67; Spain, 59; Sweden, 29; France, 200; Italy, 7. Patients from Portugal, Spain, and Sweden all had the Val30Met (V30M) TTR variant, whereas 69% and 14% of patients from France and Italy had the V30M TTR variant, respectively. Among all-comers with a pre-OLT PND score (n=322/355), 61% underwent transplantation at PND stage of 0 or I, 26% at stage II, 12% at stage IIIa or IIIb, and <1% at stage IV. Within the Italian cohort, 43% underwent transplantation at stage I, 43% at stage II and 14% at stage IIIb. Following OLT, 33% of all-comers (n=107/322) experienced a PND progression; the percent of patients who progressed varied by country (Sweden, 31%; Portugal, 21%; Spain, 37%; France, 37%). Overall, median time from transplantation to PND progression, was 2.9 years (range: 2.5-4.5 years); median time to progression within the individual countries included: Portugal, 4.5 yrs; Spain, 2.6 yrs; Sweden, 4.0 yrs; France, 2.5 yrs; Italy, 3.0 yrs. Conclusions: These preliminary data suggest that despite receiving an OLT, disease progression may not be halted in some patients with FAP. Based on this multi-national population of FAP-OLT patients with both V30M and non-V30M TTR genotypes, clinically meaningful neuropathy progression was observed in a median of 2.9 years after OLT. These findings suggest the need to carefully monitor FAP-OLT patients for signs of progression.
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FAP in India: a first genetically proven case Daniel Pan 1* , Jérôme Bouligand 2 , Anne Guiochon-Mantel 2 , David Adams 3 A 28 year old male with a background of abdominal tuberculosis living in Tekhand slum district of Delhi presented with two and half year history of recurrent loose stools following tingling sensation in the upper and lower limbs, as well as weakness in the lower limbs. He also reports erectile dysfunction and postural hypotension. He had lost weight : kilos. Upon examination the patient has lost all sensory perception in the lower limbs up to the upper thigh with severe wasting and dull lower limb reflexes. There was pes cavus and a high stepping gait. Investigations revealed persistent circumferential thickening in the abdomen on CT. Sural nerve biopsy showed inflammation with demyelination and amyloidosis. There was a loss of parasympathic/ sympathetic reactivity. Bone marrow biopsy revealed amyloid deposits compatible with secondary AA with increase in anti-LKM antibodies. Endoscopy revealed increased inflammation in the lamina propia. Familial amyloid polyneuropathy was suspected, and TTR Sanger sequencing revealed detection of a missense mutation of Val30Ala at a heterozygous state.
Transthyretin familial amyloid polyneuropathy (TTR-FAP) is a rare systemic disease due to endoneurial amyloid deposit, and is one of the most severe disabling hereditary peripheral neuropathies in adults. It has been described clinicopathologically in 1952 by Corino Andrade in north of Portugal and genetically in 1984 by Maria Joao Saraiva. TTR-FAP has long been considered an endemic disease in Portugal, Sweden and Japan, although sporadic cases have also been reported in Europe initially in France and the UK. There is genetic heterogeneity in TTR-FAP, with Val30Met being the most frequent genotype in the world. Val30Ala is a rare mutation, which have previously been described in the Chinese population.
In this manuscript, we document to our knowledge the first genetically proven case of FAP in India, a populated country of more than 1.2 billion inhabitants, and a detailed description of the patient case, as well as family investigations are provided. The patient is awaiting for antiamyloid treatment. Written informed consent for publication of their clinical details and/or clinical images was obtained from the patient /parent/guardian/ relative of the patient. (n=18); SSA/wild-type ATTR was reported by 13 patients. 57%, 33%, and 77% of pts with ATTR, non-TTR, and wild-type ATTR were male, and average age at diagnosis was 54, 55, and 71 years, respectively. The most frequently involved organs were heart and nervous system in pts with ATTR, kidney and nervous system in pts with non-TTR, and heart in pts with wild-type ATTR. In pts with ATTR, non-TTR, and wild-type ATTR, the correct diagnosis was made within 6 months in 35%, 22%, and 46% of pts, respectively. For pts with ATTR, the correct diagnosis was most commonly made by a cardiologist (24%), neurologist (22%), or primary care physician (11%). For those with non-TTR, the correct diagnosis was most commonly made by a hematologist (22%), nephrologist (17%), or specialist at an amyloidosis center (17%). Pts with wild-type ATTR most commonly received the diagnosis from cardiologists (62%). Across groups, less than one-third of pts knew how to enroll in a clinical trial, but half would consider participating if more informed.
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Conclusions: A correct diagnosis of hereditary or wild-type ATTR amyloidosis often requires numerous physician visits to different medical specialists and often occurs when disease is advanced. Responses obtained in this survey highlight the challenges experienced by pts with these rare diseases. These data may identify opportunities to educate pts and physicians in order to expedite diagnosis, facilitate appropriate disease management and access to clinical trials, and ultimately improve pt survival.
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Glu89Gln (TTR, prealbumin) . So far it has been identified more than 100 mutations in the transthyretin gene and type of causal mutation is also characterized by a clinical picture of the disease. The most common variant is a neuropathic disease. Characteristic feature is an endemic occurrence with very low incidence in the Central Europe countries.
Methods: The aim of this communication is to present case of a patient with an inherited form of the TTR amyloidosis which is extremely rare in the Czech Republic.
Results: 25-year-old patient was examined for a history of two years lasting and gradually progressing paresthesias of the lower limbs associated with instability, reduced muscle strength, dysesthesias and peroneal gait. In the last year, also present with intermittent dyspepsia, loss of weight was 10 kg (BMI 16.3, BMI 717.2) . On the basis of clinical and EMG finding he was treated as CIDP with i.v. pulses of methylprednisolone, followed by maintenance therapy with prednisone and azathioprin. Afterwards the dyspepsia developed. Gastric endoscopy with biopsy revealed massive deposits of amyloid. Family history clarify amyloidosis with neurological impairment in the patient's mother. Immunohistochemistry confirmed strong positivity of transthyretin in amyloid masses. The amyloid stained specifically with antibodies to transthyretin.
Conclusions:
We report a patient with a very rare TTR p.Asp58Val mutation who presented with typical clinical picture of late-onset TTR-FAP with predominant polyneuropathy. Due to advanced stage of disease the patient had no indications for tafamidis or liver transplantation. This variant has previously been identified in a Ghanaian male who presented at similar age with predominant polyneuropathy (Lachmann, 2002) . In our patient this mutation has occurred de novo, which is uncommon in TTR-FAP. Consent to publish: Written informed consent for publication of their clinical details and/or clinical images was obtained from the patient /parent/guardian/ relative of the patient. Objective: Transthyretin (ATTR) amyloidosis is the commonest form of hereditary amyloidosis. More than 120 amyloidogenic TTR mutations have been described and with few exceptions, these are rare, reported only in isolated kindreds. We describe here the clinical characteristics and disease course in 11 patients with novel TTR mutations. The structural consequence of replacing the wild-type amino acid with variant was examined in silico using PyMOL, an online molecular visualization tool. Methods: 11 individuals with features raising the possibility of ATTR amyloidosis were referred to the UK NAC for clinical and laboratory investigation.
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Results: Median (range) age at onset of symptoms was 58 (44-68) years; median age at diagnosis was 61 (46-74) years. Three patients presented with progressively worsening shortness of breath and chest tightness on exertion, six suffered with gradually progressive neuropathy, one was hospitalised with heart failure and oedema whilst one was asymptomatic but had a family history of FAP. Amyloid deposits were identified in biopsies in all cases by Congo red staining and were confirmed to be of ATTR type by immunohistochemistry. Genetic analysis revealed five novel variants: p.E74L (E54L), p.E74Q (E54Q), p.A101V (A81V), p.H110D (H90D) and p.I127F (I107F). The cohort was followed for a median (range) of 4 (1-7) years after referral during which six patients died of cardiac amyloidosis. Median (range) age at death was 66 (60-80) years, and median (range) time from onset of symptoms to death was 8 (4-16) years. In silico analyses showed small structural changes associated with each of the novel TTR variants. Thus we speculate that these molecular modifications may have contributed to their amyloidogenic properties. Furthermore, we identified the substitutions resulting in the p.E74L/Q (E54L/Q) to likely have a particularly deleterious impact on the TTR molecule. Multiple sequence alignment revealed the native p.E74 (E54) amino acid to be evolutionary highly conserved with no alternation of this residue among other species, indicating that it must be structurally and functionally important. Indeed, the side chain of the p.E74 (E54) forms hydrogen bonds with thyroxine, thus plays vital role in its transport. Replacement of this negatively charged, polar glutamic acid with the hydrophobic leucine residue may abolish this interaction.
Conclusions:
We describe the clinical phenotypes and disease course in 11 patients with novel TTR mutations. Each variant was found in at least two unrelated individuals who had similar clinical features, which make it highly unlikely to be an incidental finding. Immunohistochemistry confirmed that amyloid fibrils were composed of TTR, which in conjunction with the characteristic clinical features of ATTR amyloidosis
Orphanet Journal of Rare Diseases 2015, Volume 10 Suppl 1 http://www.ojrd.com/content/10/S1/I1 manifesting with cardiomyopathy and neuropathy, indicates that these novel TTR mutations were indeed the cause of ATTR amyloidosis in our patients.
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Transthyretin familial amyloid polyneuropathy (TTR-FAP) Echocardiography was used to analyze LVST, E/E' and GLS. All participants also had BNP blood testing. 99mTc-DPD scintigraphy assumed as a reference method showed CA in 18 patients (51%, CA group) and no accumulation in 17 patients (no CA group). In descending order of accuracy, LVST >14 mm, E/E' >6.6, GLS <14.1, BNP >129 pg/ml, and an overall abnormal ECG showed good capability to distinguish patients with and without CA. All these parameters were predictors of CA in univariate analysis while low-voltage QRS showed the worst performance. LVST >14 mm (p = 0.002) was the best independent predictor of CA, achieving sensitivity of 78% and accuracy of 89%. However, a LVST >14 mm (p = 0.005) plus an abnormal ECG (p = 0.03) show together a higher sensitivity, equal to 89%, in identifying CA. An integrated evaluation of ECG and echocardiography is a sensitive and low-cost technical approach to identify CA in patients with transthyretin gene mutation.
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TTR sequencing should be considered ahead of hypertrophic cardiomyopathy in Afro-Americans Patients with hereditary ATTR amyloidosis undergoing evaluation for liver transplantation were consecutively selected for manometry (n = 19), and for each patient three age and gender matched controls (n = 57) with functional GI disorders were selected for comparison. Patients with an age at onset of 50 years or more were defined as late-onset cases. Nonparametrical tests were used for all statistical analyses. Results: The patients' median age at examination was 52.8 (30.8-66.5) years and the median duration of symptomatic disease was 2.3 (0.5-9.7) years. A majority (89%) of the patients carried the V30M mutation, 58% had GI symptoms and 84% had a PND score of I. Small bowel manometry was judged to be normal in 42% of the patients and 74% of the controls (p = 0.01). Patients displayed significantly more phase III migrating motor complexes during day-time than the controls (in median 4 vs. 2, p <0.01), and had a delayed response to octreotide (in median 5.0 min vs. 3.8 min, p = 0.02). Low-amplitude complexes were more common in patients than in controls (16% vs. 4%), however, this difference did not reach statistical significance (p = 0.10). Among the patients, late-onset cases showed a longer delay in octreotide response (in median 5.4 vs. 4.3 min, p = 0.03), but no major difference related to gender, presence of GI symptoms, PND score or TTR mutation was found for any of the variables. Conclusions: Patients with early-stage hereditary ATTR amyloidosis only showed minor abnormalities in their small bowel motility. The main finding was a delayed response to octreotide injection, which may reflect an autonomic neuropathy and changes in the neuroendocrine system of the gut, including a depletion of interstitial cells of Cajal and a reduction of endocrine cells. Surprisingly, late-onset cases had a longer delay in octreotide response, however, this might be an agerelated finding.
P37
What to do when the neuropathy worsens after successful heart and liver transplantation in a Glu89Lys Transthyretin Amyloidosis? (3.9±3.7 vs. 2.0±1.9 respectively; p=0.001). The uptake by soft tissues was also greater in the DPD compared to HMDP group (B/ST: 3.6±2.0 vs. 5.7±2.9 respectively; p<0.0001).
Conclusion: The present study shows that in patients with TTR FAP, the uptake of DPD in heart and other soft tissues is superior to that of HMDP. This suggests that DPD should be prioritized for initial assessment of patients suspected of cardiac involvement of TTR-related amyloidosis.
Further study is required to assess whether this difference impacts the diagnostic performance and whether DPD is more accurate for the assessment of therapy response.
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The Background: In familial aTTR amyloid polyneuropathy (FAP) cardiac involvement is of major prognostic value. Two approaches using radionuclide imaging proved relevant in the assessment of aTTR-related cardiac amyloidosis: detection of amyloid deposits with disphosphonates (DPD) and of sympathetic denervation with MIBG. The study aimed to compare the respective value of both approaches in patients with aTTR-FAP with suspected cardiac involvement. Methods: We prospectively included 76 consecutive patients identified from the database of the French National Reference Center for Amyloidosis with genetically proven aTTR-FAP (males 62%, Val30Met: 42%, domino-liver transplantation 13%, symptomatic 57%, interventricular septum (IVS)≥12 mm: 52%; left ventricular ejection fraction: 63±10%). They underwent both MIBG and DPD scintigraphy in a delay <3 months. For DPD SPECT, acquisitions were performed 3 hours after tracer injection. Cardiac uptake was visually scored as present or absent and quantified by the ratio between 3D isocount volume of interest generated over the myocardium and a standard volume in lung (H/L). For MIBG, heart-to-mediastinum ratio (HMR) was calculated on planar acquisitions performed 4 h after tracer injection. Cardiac MIBG was classified as normal, mildly, moderately, or severely abnormal. Results: The delay between DPD and MIBG 6±12 days. DPD was abnormal in 30 patients (39%) and MIBG in 50 patients (66%; p=0.002). When MIBG was normal (n=26), BS was normal except for 1 patient. When MIBG was abnormal (n=50), BS was normal in 21 patients (42%). The uptake of DPD increased with the denervation score (normal: 0.6±0.2; mild: 0.6±0.4, moderate: 3.4±3.3; severe: 4.5±3.7; p<0.001 between normal and moderate/ severe). In patients with a previous domino liver transplantation (n=10), the overall pattern was similar. In asymptomatic patients (n=31), all those with a normal MIBG (n=17) had a normal DPD; MIBG was abnormal in 45% (n=14), 50% had a normal DPD. In addition, HMR was greater (1.8±0.3 vs. 1.6±0.4; p=0.008) and H/L was lower (1.7±2.3 vs. 3.2±3.5; p=0.04) compared to symptomatic patients. Conclusion: In patients with suspected cardiac involvement of aTTR-FAP, MIBG was abnormal more frequently than DPD. In particular, DPD abnormalities are delayed compared to MIBG since it was abnormal only when denervation was moderate or severe. In the group of asymptomatic patients, MIBG was abnormal in 45% of patients, and only half of those with cardiac denervation had a positive BS. This suggests that innervation abnormalities as seen with MIBG are more frequent and earlier than significant amyloid deposits as seen with Diphosphonates.
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Cardiac extracellular volume quantified with T1 mapping techniques reflects degree of cardiac and neurological involvement in Hereditary Transthyretin Amyloidosis Esther González-López 1* , María Gallego-Delgado 1 , Francisco Muñoz-Beamud 2 , Juan Buades 3 , Lucía Galán 4 , Jose Luis Muñoz Blanco 5 , Jesús González-Mirelis 1 , Pablo García-Pavía 1
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Diagnostic value of fat aspirates for amyloidosis in 950 patients JA Gilbertson * , NA Botcher, D Rowczenio, C Whelan, HJ Lachmann, A Wechalekar, JD Gillmore, PN Hawkins National Amyloidosis Centre, UCL Division of Medicine, NW3 2PF, London, UK Orphanet Journal of Rare Diseases 2015, 10(Suppl 1):P50
Background: Aspiration of abdominal subcutaneous fat is a simple outpatient procedure that is well established in management of patients with amyloidosis and is particularly useful when investigating the cause of organ dysfunction and more specifically in the context of a suspicion of amyloidosis. At the National Amyloidosis Centre (NAC), fat aspirates are routinely obtained in patients whom amyloid has not been previously confirmed. To date we have performed 950 fat aspirates to seek the presence of amyloid and identify the respective amyloid fibril protein. Thirty percent (290 cases) of the total aspirates sampled were found to contain amyloid. It was possible to conclusively type the fibril protein using immunohistochemistry (IHC) in 188 of these cases, thereby thwarting the need for a more invasive diagnostic biopsy or further diagnostic tests. Method: Abdominal fat tissue is aspirated and smears are prepared on to glass slides for Congo red staining. The remainder of the fat tissue aspirated is briefly fixed in formalin, double embedded in agar and then into a paraffin block (FFPE) for routine histology and IHC. Once amyloid has been confirmed IHC is performed using a panel of monospecific antibodies against known amyloid-forming proteins in an attempt to identify the amyloid fibril. Interpretation of all stained slides is carried out by two experienced people with and without crossed polarizing filters. Results: We found 97% concordance between the smear and the block results. Two percent of the smears gave a negative result for amyloid when the corresponding FFPE was positive, whereas 1% of the smears where positive when the FFPE was negative. Of the samples taken 60% did not contain any amyloid and 10% gave insufficient material for interpretation. Among the amyloidotic samples, IHC identified 25% as ATTR, 2% of other types (AA, AapoA1 and ALYS), 42% AL amyloid and 31% gave no immuno specific staining. Conclusion: Aspiration of abdominal subcutaneous fat is a valuable method in diagnosing amyloid, in 30% of cases preventing the need for a more invasive biopsy. There was a difference of 3% between the smear and the FFPE indicating that all representative tissue taken must be analysed to give a correct diagnosis. Only 42% of patients with negative samples went on to have a further tissue biopsy, over half of these samples did not contain any evidence of amyloid. Ten percent of the fat aspirates gave insufficient adipose material for interpretation, comprising mainly of blood. Immunohistochemical identification of the amyloid fibril protein was proven in 188 cases, in 31% of the cases the precise amyloid type was only determined after genetic sequencing. TTR by IHC was identified in 25% of the cases and among these patients, 62% were later found by genetic sequencing to have a variant, with V122l (p.V142l) being most common. Of the fat aspirates that did not demonstrate amyloid, only 6% of the patients were found to have a TTR variant.
Background: wtATTR amyloidosis is an under-diagnosed and underappreciated cause of heart failure. CMR adds value diagnostically for morphological phenotype and tissue characterization. Methods: At a national referral centre, over 4 years, 87 consecutive recruited patients wtATTR amyloidosis underwent CMR. The diagnosis was confirmed by histological proof of amyloid (62%), exclusion of TTR mutations (100%) and characteristic features including bone tracer scanning (DPD grade 2-3 in 100%). CMR had precipitated the referrals in 71% of the cohort. Standard long and short axis cines derived the presence and distribution of LVH, relative wall thickness (RTW), inversion of the septal curvature and LV remodeling patterns were determined. Results: There were 82 patients with wt ATTR amyloidosis (82 males (94%), age 75 ± 7 years). Patients with wtATTR amyloidosis had increased LV mass index, EF at the lower limit of normal range and markedly reduced indexes of longitudinal function. LV mass was always large compared to cavity size, as expected. Howeverthere was far more asymmetric hypertrophy than expected -61% of patients had the septum >1.5x thicker than the posterior wall. Inversion of the septal curvature was found in 34% of patients, features typically associated with hypertrophic cardiomyopathy. Tissue characterization with LGE was typical of amyloidosis in 100% of cases (transmural LGE in 73%, subendocardial in 27%).
Conclusions: CMR is a major source of diagnosis of wtATTR. The majority of patients with wtATTR amyloidosis have a pattern of hypertrophy traditionally thought associated with hypertrophic cardiomyopathy rather than amyloid with asymmetric septal hypertrophy and reverse septal curvature. Background: Transthyretin related familial amyloidotic polyneuropathy (TTR-FAP) is an inherited form of amyloidosis, leading to death in about 10 years in most cases for cardiac failure or wasting syndrome. Previous study showed that modified body mass index (mBMI) was related to time before death, duration of gastrointestinal disturbances, malabsorption and functional capacity. Futhermore, outcome after liver tranplantation was greater in patients with an mBMI over 600.
P52
Patients: We report two TTR-FAP patients, carrying respectively the Thr49Ala and the Glu89Gln mutations, in whom nutritional status worsened despite diet modification, hypercaloric supplement and two important therapeutic approaches such as liver transplant and tafamidis meglumine. In both case, at a late stage of the disease, a peripherally inserted central catheter (PICC) was placed and the parenteral nutrition started. Results: The parenteral nutrition added to oral nutrition allowed to improve their nutritional status and clinical conditions as documented by increase of body weight and mBMI. Moreover, we recorded reduction of autonomic symptoms including postural hypotension, nausea and diarrhoea and amelioration of quality of life. Conclusion: Our experience suggests that parenteral nutrition administered by PICC may be useful in reducing complications and disabilities in TTR-FAP patients, even when all dietary adjustments have been ineffective. Reasonably, the improvement in nutritional status may prolong survival in TTR-FAP patients.
Background: In Brazil, the most prevalent cases of TTR-related amyloidoses is the V30M variant due the Portuguese colonization. Our group has stablished a center for molecular diagnostic of FAP. Since then, we have sequenced almost one hundred patients form the University Hospital and their relatives. Recently, we identified a patient with a severe cardiomyopathy. This patient has a German ancestry and the sequence of his TTR gene revealed the presence of a new mutation, namely A19D. This patient presented heart failure and was classified by the NIHA as IV. We have also identified a patient, 66-years old, from a family with African ancestry, which bears the typical V122I mutation. This patient presented carpal tunnel syndrome and two years later developed heart failure that progressed to NYHA III. The main goal of the present work is to characterize the Brazilian population with FAC by combining bioinformatics and biophysical studies.
Methods: We built a model for A19D by using FoldX (http://foldx.crg.es/) with the original WT-TTR structure as deposited in the PDB under code 1F41. The toxicity of amyloid aggregates composed of A19D and V122I were evaluated by using cell viability assay in primary culture of murine cardiomyocytes and fibroblasts as well as N2a cell line. Results: Initially we used the bioinformatics tool FoldX to predict the thermodynamic stability of the new mutant A19D. Our predictions have shown that the insertion of mutation caused a decrease in the thermodynamic stability of the protein and cause an electrostatic clash in the region of thyroxine channel that could facilitate their dissociation. A19D was purified heterologously and biophysical studies demonstrated that this mutant is a dimer and not a tetramer as wild type structure. The crystallographic structure of A19D is identical of wild type TTR. Thermodynamic studies with A19D indicated that it has a lower stability than the wild-type protein and other mutants. This new mutant has a faster aggregation kinetics forming amyloid fibers in two hours as shown by images. Amyloid aggregates of A19D and V122I were incubated with primary culture of cardiomyocytes and fibroblasts from murine heart and also in N2a cell line. The viability assay showed that the oligomers of A19D and V122I are toxic for cardiomyocytes and neuroblastoma cells and interestingly fibroblasts also suffer injury in the presence of these aggregates.
Conclusions: The recent consolidation of TTR diagnosis in our University Hospital led to the identification of a rare, new variant of TTR in Brazil, namely, A19D, as well as the common V122I variant. A19D presented a marginal thermodynamic stability as inferred by bioinformatics and by biophysical studies with the purified protein. A19D showed to be dimer in solution. The viability assay shows that toxic mechanism displayed by this new mutant can be directly correlated with the aggressiveness observed in the disease developed by the patient.
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Life paths of familial amiloidotic polyneuropathy patients: a descriptive study Alice Lopes 1* , Alexandra Sousa 1 , Isabel Fonseca 1 , Margarida Branco 1 , Carla Rodrigues 1 , Paula Freitas 2 , Teresa Coelho 1 1 important distress factor, eventually making them more vulnerable to psychological distress and psychiatric disease. During childhood, youth, and as young adults, a great number of these patients were obliged to become caregivers and this implied a change of roles in the family. These results point to a very important psychosocial charge that FAP imposes to patients throughout their lives, since childhood and youth.
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Axon reflex-mediated vasodilation is reduced in proportion to disease severity in familial amyloid polyneuropathy Thierry Kuntzer 1* , Irène Calero-Romero 2 , Bernard Waeber 2 , Francois Feihl 2 Background: Axon reflex-mediated neurogenic cutaneous vasodilatation in response to histamine reflects C-fibre dysfunction. We aimed to evaluate the distribution of the vascular flare area measured by laser doppler imaging ("LDIflare area") in familial amyloid polyneuropathy (FAP) and in healthy volunteers.
Methods: Twenty-one subjects were contacted to participate in this study. Eleven FAP patients and 10 normal volunteers were recruited for this hospital's ethics committee approved study. Confirmed genetically FAP patients were recruited from our registry, and were prospectively reexamined to determine the frequency of neuropathic motor, sensory, and autonomic symptoms and findings, to measure nerve conduction parameters, and to assess thermal testing performed using a Medoc TSA-II thermal analyzer. LDIflare areas were induced by iontophoresis (at 100uA for 1 min) of histamine at the forearm and at the leg. Results: Six patients had a FAP of variable severity, one had a generalized analgesia secondary to leprosy (used as positive control). Four patients had to be excluded from the analysis as it was not possible to quantify neuropathy severity (asymptomatic carriers). All but one had a Val30Met mutated TTR gene. The median neurological impairment score of the lower limbs (NIS_LL) was 9.3 (0 to 27). Half of the patients had reduced or absent sural nerve potential. The warmth detection thresholds in the feet were higher in patients group (ctrl=37.6°C, 35.3 to 38.3: patients=42.2°C, 38.2 to 48.8: p<0.015), indicating small fiber impairment. Compared to controls, patients had lower LDIflare areas in the legs (ctrl=13.0, 9.2 to 19.8cm2: patients=5.8, 2.7 to 11.4cm2) and in the forearms (ctrl=21.7, 14.3 to 26.1cm2: patients=12.4, 4.2 to 20.6 cm2). However, the differences were statistically different for the legs only (p=0.015) (p=0.089 for the arms). There was an excellent correlation between the degree of LDIflare area and NIS_LL (Spearman's rank correlation for forearm; r = -0.71, p<0.074: for leg; r = -0.84, p<0.019).
Conclusion: Our study underscores that in FAP patients, the amount of LDIflare area is reduced in proportion to disease severity.
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Patients with hereditary ATTR amyloidosis experience an increasing burden of illness as the disease progresses David Adams 1* , Oved Amitay 2 , Teresa Coelho 3 1 Introduction: Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) is a worldwide autosomal dominant disease due to point mutation of TTR gene. The main endemic area is Portugal, associated with V30M variant and an early onset (EO) (mean age 30 yo). Phenotype is a progressive length dependent small fiber polyneuropathy with autonomic dysfunction and cardiac conduction disorders; the median survival is 12 years. France is a prototypic non endemic country, characterized by sporadic cases in 50%, a late onset (LO>50 yo) in 75%, a genetic heterogeneity (41 variants ; V30M in 55%). Liver transplantation (LT) is the gold standard treatment allows to stop progression of the neuropathy in EO V30M patients and to prolonge significantly the survival. Tafamidis, a TTR kinetic stabilizer, received marketing authorization in Europe for stage 1 FAP (walking unaided) allowing to slow progression of the neuropathy. Aims of the study was to assess the place of tafamidis in the management of TTR-FAP.
Methods: In a population of 131 patients diagnosed during period (2008) (2009) (2010) (2011) (2012) . Mean age : 59.3 yo SD 15.9. Stage 1 (60%) stage 2 (36%) stage 3 (4%). Mutation : V30M: 59%, non V30M variants n=18, Late onset (LO): 73.3%. mean NIS : 40.65 SD 28.6. In Stage 1 mean NIS=27.32 SD 20. Locomotion (PND score) : 71% with Walking difficulties. Patients were followed periodically (every 6 months) in consultation assessing by a questionnaire : new manifestations (sensory complaints, walking difficulties, autonomic dysfunction (digestive (gastroparesia, diarrhea), erectile dysfunction)). And on examination looking for orthostatic dysfunction.
Results: Among the 78 patients of stage 1, 56 accessed to tafamidis (73% V30MTTR), 16 underwent LT, 6 were lost of follow-up. The follow-up ranged from 0.5-4.5 years. Fourteen patients (25%) remained stable for > 2 years under tafamidis (max 4.5 years) including 8/15 with NIS<10, 80% V30MTTR; 7/15 EO. Twenty three/56 pts (41%) worsened with increased or onset walking disability (n=14); daily diarrhea (5) with anal incontinence (3); extensive painful and sensory neuropathy (n=2), hand weakness (n=1), onset of erectile dysfunction (n=1). Worsening occurred during the first year in 65%, between 1 to 2.5 years in 35%. Most of them had a NIS ≥10 (87%), 69% V30MTTR; 48% LO. Among the 23 patients who worsened, 12 were enrolled in clinical trials with TTR gene silencing ; 11 underwent LT. Conclusions: Treatment of stage 1 TTR-FAP by tafamidis requires a close and long term monitoring of patients including a detailed questionnaire on walking disability, autonomic dysfunction, extension of pain and sensory loss. In case of significant progression in these items, a switch to clinical trials or LT should be done.
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The rehabilitation in the management of Transthyretin Familial Amyloid Polyneuropathy Agnès Morier 1* , Alyssa De Sousa 2 , Colombe Lemoine 1 , Cecile Cauquil 1 , Marie Théaudin 1 , David Adams 1 , Hervé Chanut 2
Methods: To be able to offer a well-adapted rehabilitation program, the rehabilitation therapists have put into place assessments in order to estimate the different clinical manifestations described by the patients. The pain, the paresthesia and strength deficiency will be evaluated in this way, and their evolution followed up, thanks to comparative test. We have been looking for tools to be able to evaluate the clinical manifestations and their evolution. Results: For that purpose, we have chosen comparative tests that allow to measure quantitative and qualitative results. The pain and the tiredness are evaluated with visual analogue scales, the strength with muscular testing and dynamometer, the functional aspect is tested with an evaluation of: the standing upright; the handicap situation and the 6 minute walking test. The assessments' have improved in recent years with more precise tools. Conclusion: It is essential to stay as close as possible to the felt effects of the patients to deal with unbiased variations and put into place an adapted rehabilitation program.
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